Connect public, paid and private patent data with Google Patents Public Datasets

Composition and Process for Bone Growth and Repair

Download PDF

Info

Publication number
US20060246150A1
US20060246150A1 US11383309 US38330906A US2006246150A1 US 20060246150 A1 US20060246150 A1 US 20060246150A1 US 11383309 US11383309 US 11383309 US 38330906 A US38330906 A US 38330906A US 2006246150 A1 US2006246150 A1 US 2006246150A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
bone
phosphate
calcium
growth
collagen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11383309
Inventor
Kevin Thorne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zimmer Orthobiologics Inc
Original Assignee
Zimmer Orthobiologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/22Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24Collagen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1875Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02Inorganic materials
    • A61L27/12Phosphorus-containing materials, e.g. apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/22Polypeptides or derivatives thereof, e.g. degradation products
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/22Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24

Abstract

A composition for the induction of bone growth is disclosed. The composition includes a substrate, bone growth protein, and sources of calcium and phosphate. The composition is acidic which promotes high activity of the bone growth protein. The calcium and phosphate sources can be provided as an acidic calcium phosphate salt. Also disclosed are methods of the making the composition and methods of using it.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • [0001]
    This application is a continuation-in-part of prior copending U.S. patent application Ser. No. 09/746,921, filed Dec. 22, 2000.
  • FIELD OF THE INVENTION
  • [0002]
    The present invention relates to methods and compositions for the induction of bone growth in mammals and to methods for the production of such compositions.
  • BACKGROUND
  • [0003]
    A number of diseases or injuries involving bones are known for which repair, regeneration, or augmentation of bone is a desired treatment. Formation of bone in vivo involves an interaction of various inductive proteins which act by causing a differentiation of mesenchymal cells into cartilage and then bone-forming cell lines. This mechanism is not completely understood. However, in efforts to improve orthopedic procedures, purified protein mixtures and recombinantly produced proteins have been developed which stimulate osteoinductive activity.
  • [0004]
    In general, autogeneous bone grafts have been viewed as the standard for restoring skeletal defects. However, autogeneous sources of bone in human beings are limited, expensive and painful to obtain. Accordingly, materials such as demineralized bone matrix have been developed to augment or replace autogeneous bone grafts. However, an alternative to demineralized bone matrix is desired to improve the ease of use, economy of product manufacture and to eliminate the potential of disease transfer or immune system incompatibilities. To date however, an acceptable substitute has not been identified.
  • [0005]
    Currently the clinical potential of composite implants containing a mixture of bovine tendon collagen and a proprietary bone morphogenic protein mixture, with demineralized bone matrix powders and simulated body fluid is being evaluated. While a number of advances have improved the activity of osteoinductive factors such as those present in bone morphogenic protein mixtures, their clinical application has been limited, in part, by the requirement for a superior delivery vehicle. Resistance to the use of demineralized bone matrix in certain cultures, as well as the desire to enhance the activity of the bone morphogenic protein mixture to reduce cost, speaks to the desire to develop substitutes for demineralized bone matrix.
  • [0006]
    The present invention provides compositions that can be used as bone graft substitutes to obtain a product with an improved osteoinductive response for growth factors in degradable implants for skeletal regeneration. The compositions of the present invention are easier to use and more economical to manufacture than demineralized bone matrix, and they eliminate or significantly reduce the potential of both disease and pathogen transfer and immune system incompatibilities.
  • [0007]
    Numerous materials have been experimentally evaluated as alternative delivery vehicles for osteoinductive growth factors. The materials previously assessed by reconstructive surgeons and scientists include, without limitation, hydroxyapatites, tricalcium phosphates, aliphatic polyesters, cancellous bone allografts, human fibrin, plaster of paris, apatite wollastonite glass ceramics, titanium, devitalized bone matrix, non-collagenous proteins, collagen and autolyzed antigen extracted allogenic bone. None of these materials have been found to be entirely satisfactory.
  • [0008]
    Other growth factor carriers containing calcium phosphate additives have been developed. For example, a macroporous collagen sponge containing a mixture of a-tricalcium phosphate (α-3CaO.P2O5) and hydroxyapatite (3.33CaO.P2O5(OH)2) has been developed. Alternatively, a macroporous collagen sponge that contains precipitated hydroxyapatite has also been disclosed (U.S. Pat. No. 5,776,193). The composition of such products are consistent with the prevailing view that hydroxyapatite is the preferred calcium phosphate source for bone graft substitutes or extenders due to its compositional similarity with the mineral component of natural bone.
  • [0009]
    There remains a desire for improved compositions for the induction of bone growth in animals that address the problems of existing compositions and products.
  • SUMMARY
  • [0010]
    As noted above, hydroxyapatite has long been considered a preferred source of calcium phosphate in bone graft substitutes. Indeed, evidence suggests that the inclusion of hydroxyapatite in bone graft substitutes does provide benefits related to osteoblast adherence. Thus, hydroxyapatite shares a compositional similarity to naturally occurring bone mineral and stimulates certain elements of the bone formation cascade. Certain hydroxyapatite bone graft substitutes have also been preferred as they are generally characterized by having a neutral or basic pH when implanted under normal physiological conditions. Despite these long-believed potential benefits and the resultant preference for hydroxyapatite containing bone growth substitutes, the inventor has now shown that the addition of calcium phosphate materials having a neutral or basic pH, such as hydroxyapatite, to collagen actually hinders the osteoinductive activity of bone growth proteins in vivo.
  • [0011]
    The present invention is directed to a bone growth composition which includes an acidic substrate and a bone growth protein, wherein the bone growth protein is characterized as having a first activity at neutral or basic pH and a second, higher activity at acidic pH. The acidic substrate preferably comprises a source of calcium and a source of phosphate. The composition also may include an acidic buffering potential in physiological solution. In another embodiment, the composition further includes a biocompatible buffering agent to maintain the acidity of the composition. In further alternative embodiments, the sources of calcium and/or phosphate can be salts such as monocalcium phosphate, calcium hydrogen phosphate dihydrate, or calcium pyrophosphate. The substrate can comprise collagen, fibrin, alginate, one or more synthetic polymers (such as polyethylene glycol (PEG), functionalized PEG, aliphatic polyesters, polylactic acid (PLA), or polyglycolic acid (PGA)), or mixtures thereof. The bone growth protein can be one or more purified bone growth proteins (each protein can be purified independently or collectively from allograft, xenograft, or autograft bone), recombinantly produced bone growth proteins, or mixtures thereof. In a preferred embodiment, the bone growth protein includes a purified bone growth protein composition known as Bone Protein Mixture or BPM.
  • [0012]
    An embodiment of the present invention also includes a process for producing an implantable bone growth composition. The process includes producing a dispersion of collagen fibrils containing a solubilized sodium phosphate salt. The process may further include adding a calcium chloride salt to the dispersion of collagen fibrils to precipitate a calcium phosphate salt onto the surface of the collagen fibrils to produce an implantable bone growth composition. Alternatively, the process can include making the dispersion with a calcium salt and adding a phosphate salt.
  • [0013]
    The present invention also includes a process for the induction of bone formation in a mammal, which includes implanting a bone growth composition of the present invention in a mammal. Such a process can include the use of the bone growth composition in a joint replacement operation (e.g., hip, knee, shoulder, elbow, or ankle, among others), a spinal fusion, repair of periodontal defects, treatment of osteoporosis, skeletal augmentation, repair of bone defects, or repair of bone fractures.
  • [0014]
    The composition of the present invention and products made therewith are superior materials for use as a demineralized bone matrix replacement. It has been found that the calcium source, the phosphate source, their collective pH, and the acidic buffering potential each have independent beneficial effects for bone growth induced by the present composition. In addition, the novel processing technology for producing such materials produces collagen sponges with dramatically superior physical properties. The products are collagen dispersions containing a calcium phosphate salt on the surface of the collagen fibrils, resulting in the formation of water stable, collagen sponges with superior physical properties. Composite products provide both improved physical properties and superior osteoinductive performance. The products can be rapidly and cost-effectively manufactured, and can reduce the required doses of osteoinductive proteins. These composites provide significant economic savings and eliminate potential disease transfer due to the elimination of the use of demineralized bone matrix. Additionally, the composites provide more reproducible clinical results, allow simpler surgical application, and better maintain physical dimensions during use.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0015]
    FIG. 1: Indicates location of the subcutaneous implant sites in the upper quadrants of a rat's abdomen and dorsal thorax.
  • [0016]
    FIG. 2: A. Explant mass of disks composed of osteoinductive compounds at time of harvest, normalized to average value measured against controls containing only collagen and bone proteins.
  • [0017]
    B. Average and normalized values of explant mass at time of harvest.
  • [0018]
    FIG. 3: A. Histology scores of disks composed of osteoinductive compounds at time of harvest normalized to average value measured against controls containing only collagen and bone proteins.
  • [0019]
    B. Average and normalized histology scores at time of harvest.
  • [0020]
    FIG. 4: A. Mineral concentration of disks composed of osteoinductive compounds at time of harvest normalized to average value measured against controls containing only collagen and bone proteins.
  • [0021]
    B. Average and normalized mineral concentration at time of harvest.
  • [0022]
    FIG. 5: A. Mineral mass of disks composed of osteoinductive compounds at time of harvest normalized to average value measured against controls containing only collagen and bone proteins.
  • [0023]
    B. Average and normalized mineral mass at time of harvest.
  • [0024]
    FIG. 6: A. Explant mass of disks composed of osteoinductive compounds at time of harvest normalized to average value measured against controls containing collagen, bone proteins and devitalized bone matrix.
  • [0025]
    B. Average and normalized values of explant mass at time of harvest.
  • [0026]
    FIG. 7: A. Histology scores of disks composed of osteoinductive compounds at time of harvest normalized to average value measured against controls containing collagen, bone proteins and devitalized bone matrix.
  • [0027]
    B. Average and normalized histology scores at time of harvest.
  • [0028]
    FIG. 8: A. Mineral concentration of disks composed of osteoinductive compounds at time of harvest normalized to average value measured against controls containing collagen, bone proteins and devitalized bone matrix.
  • [0029]
    B. Average and normalized mineral concentration at time of harvest.
  • [0030]
    FIG. 9: A. Mineral mass of disks composed of osteoinductive compounds at time of harvest normalized to average value measured against controls containing collagen, bone proteins and devitalized bone matrix.
  • [0031]
    B. Average and normalized mineral mass at time of harvest.
  • [0032]
    FIG. 10: shows the influence of adding a calcium source, a phosphate source, or both a calcium and a phosphate source to the implanted composition at different acidic buffering capacity on the histology score.
  • [0033]
    FIG. 11: shows the influence of adding a calcium source, a phosphate source, or both a calcium and a phosphate source to the implanted composition at different acidic buffering capacity on the relative mineral mass.
  • [0034]
    FIG. 12: Box plot representations of average (inter-animal) and relative (intra-animal) explant mass when supplemented with various calcium phosphates.
  • [0035]
    FIG. 13: Box plot representations of average (inter-animal) and relative (intra-animal) mineral mass when supplemented with various calcium phosphates.
  • [0036]
    FIG. 14: Box plot representations of average (inter-animal) and relative (intra-animal) histological scores when supplemented with various calcium phosphates.
  • [0037]
    FIG. 15. Photomicrographs representing Average Histological differences between samples containing various calcium phosphate additives (7 mg, 50 wt. %) [2× magnification, processed with H&E/Von Kossa (left)and toluidine blue tissue stains (right)]
  • [0038]
    FIG. 16: Influence of temporary pH of the paste of Example 4 on induced explant and mineral mass values.
  • [0039]
    FIG. 17: Influence of temporary pH of the paste of Example 4 on induced bone quality.
  • [0040]
    FIG. 18: Overview of natural metabolic regulation of bone remodeling and healing.
  • DETAILED DESCRIPTION
  • [0041]
  • [0042]
    The natural process of bone resorption and subsequent bone reformation occurs throughout a person's life. The process is initiated by biomechanical stimuli and localized micro-damage to skeletal tissues. Osteoclast bone resorption locally releases essential components required for bone repair and bone reformation, including: soluble calcium [Ca3+] and phosphate [PO4 3−] ions, collagen and osteoinductive bone morphogenetic proteins (BMPs). The released molecular proteins (BMPs) sequentially result in increased cellular differentiation of active osteoblasts. Active osteoblasts deposit organic scaffolds, referred to as osteoid matrices. In the presence of soluble [Ca2+] and [PO4 3−] ions, osteoid matrices are gradually converted into bone through the serial precipitation of calcium phosphate compositions. The first calcium phosphate phase to precipitate during natural bone formation is calcium hydrogen phosphate [CaHPO4 (DICAL)] (Brown. P; Constantz, B. Hydroxylapatite and Related Materials. Boca Raton, Fla.; CRC Press, 1994, 9; Francis, M.; Webb, N. “Hydroxylapatite formation from a hydrated calcium monohydrogen phosphate precursors”, Calcif Tissue Res., 6, pps. 335-342, 1971; Johnson, M. S.; Nacollas, G. “The role of brushite and octacalcium phosphate in apatite formation”. Critical Reviews in Oral Biology and Medicine, 3 [½], pps. 61-82 (1992); Brown, W.; Chow, L. C. “Chemical Properties of bone mineral”. Ann. Res. Mater. Sci., 6, pps. 212-226, 1976; Brown, W.; “Crystal chemistry of Octacalcium Phosphate”, Prog Cyrstal Growth Charact., 4, pps. 59-87, 1981). The calcium hydrogen phosphate product is then quickly and sequentially transformed into biomedical calcium phosphate compositions, including tricalcium phosphate [Ca3(PO4)2 (TCP)], octacalcium phosphate [Ca4(PO4)3(OH) (OCP)] and hydroxylapatite [Ca5(PO4)3(OH) (HA)]. FIG. 18 shows an overview of these processes.
  • [0043]
    In one embodiment, the present invention is directed toward a bone growth composition comprising a bone growth protein having a first bioactivity; and an acidic substrate; wherein the bone growth protein has a second bioactivity greater than the first bioactivity when combined with the acidic substrate. In this embodiment, the ability of the bone growth protein to induce bone growth is greater at an acidic pH than it is at a neutral and/or basic pH. The bone growth composition is particularly useful in processes of the present invention which include implanting the product in the body for the purpose of inducing bone formation in vivo. This embodiment provides an acidic substrate which can be substituted for demineralized bone matrix as a delivery vehicle that not only avoids the risks of disease/pathogen transmission associated with demineralized bone matrix use, but which also enhances the osteoinductive activity of bone growth proteins. Compositions of the present invention have been shown to improve both the quantity (e.g., mass) and quality (e.g., histological score) of bone produced with bone morphogenic protein at reduced doses.
  • [0044]
    It should be noted that while most contemplated applications of the present invention are concerned with use in humans, the products and processes of the present invention work in non-human animals as well. Induction of bone formation can be determined by a histological evaluation showing the de novo formation of bone with accompanying osteoblasts, osteoclasts, and osteoid matrix. For example, osteoinductive activity of a bone growth factor can be demonstrated by a test using a substrate onto which material to be tested is deposited. For example, osteoinductive activity can be graded or scored as disclosed in U.S. Pat. No. 5,290,763 or as is described below in the Examples.
  • [0045]
    The bone growth composition comprises an acidic substrate and includes a bone growth protein. In certain embodiments, the substrate can provide a structure for the growth of bone and an acidic environment to enhance the activity of the bone growth protein. In such embodiments, the bone growth protein can be highly active in the acidic environment of the composition and induces the production of bone.
  • [0046]
    The acidic substrate of the bone growth composition provides a structure for the various other components of the composition and also allows for the ingrowth of bone induced by the composition. More particularly, the substrate can be a matrix forming material, such as collagen, fibrin or alginate. A preferred substrate is collagen and a preferred collagen is Type I bovine tendon atelocollagen or Type I bovine dermal atelocollagen.
  • [0047]
    The acidic substrate can also comprise a compound which renders the substrate acidic. In one embodiment, the acidic substrate comprises a calcium source and a phosphate source. In a preferred embodiment, the acidic substrate comprises an acidic calcium phosphate compound. The calcium and phosphate of the compound provide an available supply of these ions for the production of bone.
  • [0048]
    In embodiments wherein the composition includes sources of calcium and phosphate, these sources can be used to locally enhance the soluble concentration of dissolved calcium [Ca2+] and phosphate [PO4 ] within and around the site of implantation of the composition. Natural bone acts as a reservoir to, inter alia, maintain constant serum concentrations of these components. It has been theorized that the rate of bone formation may be limited by the diffusion of these critical ions to the site of bone induction. In brief, bone mineralization may exhaust the local serum concentration of calcium and phosphate, after which bone mineralization is limited by the rates of both osteoclast resorption of local bone (to provide soluble calcium and phosphate ions) and diffusion of these ions to the site of bone induction. By specifically enhancing the local concentration of these critical components, such as by the use of sparingly soluble calcium phosphate additives, the amount (mass) and quality of induced bone formation can be enhanced.
  • [0049]
    Preferred sources of calcium for the composition of the present invention include essentially any acidic calcium salt, including calcium phosphate or calcium citrate. Particularly preferred sources of calcium include acidic calcium phosphate salts. Preferred acidic calcium phosphate salts include monocalcium phosphate, calcium phosphate dihydrate (also known as dical), and calcium pyrophosphate. Typically, the calcium source is present in the composition in an amount of between about 1% by weight and about 85% by weight. In one embodiment, the calcium source is present from about 45 wt % to about 85 wt %. In a further embodiment, the calcium source is present from about 50 wt % to about 80 wt % . In yet a further embodiment, the calcium source is present from about 55 wt % to about 75 wt %. In still a further embodiment, the calcium source is present from about 60 wt % to about 70 wt %.
  • [0050]
    Preferred sources of phosphate for the composition of the present invention include essentially any phosphate salt, including calcium phosphate or sodium phosphate. Particularly preferred sources of phosphate include calcium phosphate salts, and more particularly preferred sources of phosphate include acidic calcium phosphate salts. Preferred acidic calcium phosphate salts include calcium hydrogen phosphate dihydrate, monocalcium phosphate, calcium pyrophosphate, or a mixture of two or more thereof.
  • [0051]
    Typically, the phosphate source is present in the composition in an amount of between about 1% by weight and about 85% by weight. In one embodiment, the phosphate source is present from about 45 wt % to about 85 wt %. In a further embodiment, the phosphate source is present from about 50 wt % to about 80 wt %. In yet a further embodiment, the phosphate source is present from about 55 wt % to about 75 wt %. In still a further embodiment, the phosphate source is present from about 60 wt % to about 70 wt %.
  • [0052]
    The calcium source and the phosphate source can be the same material.
  • [0053]
    As noted above, preferred sources of calcium and of phosphate include acidic calcium phosphate salts. Calcium phosphates can be represented by the general chemical formula of xCaO.P2O5. The sparingly soluble calcium phosphate salts act as solution buffers. Thus, as the salts increase in calcia concentration (CaO), the pH increases from approximately 2 (x=1) to 11 (x=4). It is believed that the alkaline buffering nature of hydroxyapatite (x=3.33, about pH 9) reduces the performance of bone growth proteins. It has been found that acidic calcium phosphate salts (i.e., monocalcium phosphate (Ca(H2PO4)2), calcium hydrogen phosphate dihydrate (CaHPO4.2H2O) and calcium pyrophosphate (2CaO.P2O5)) stimulate the osteoinductive performance of bone growth proteins. In comparison to collagen composites containing devitalized bone matrix additives, collagen dispersions containing calcium hydrogen phosphate (CaHPO4.2H2O) have resulted in superior bone quality.
  • [0054]
    Alternatively, in one embodiment, the acidic calcium phosphate compound has a Ca:PO4 ratio from about 0.5 to about 1. In another embodiment, the acidic calcium phosphate compound is a highly acidic calcium phosphate mineral, by which is meant an acidic calcium phosphate mineral having a Ca:PO4 ratio from about 0.25 to about 0.5. In a further embodiment, the acidic calcium phosphate has a Ca:PO4 ratio from about 0.3 to about 0.4. The acidic calcium phosphate compound tends to lower the pH of the composition, and in the absence of other compounds that are basic, the composition will have an acidic pH.
  • [0055]
    Thus, in preferred embodiments, the composition of the present invention uses calcium phosphate salts to (1) control local pH (to enhance/control bone growth factor release activity by providing protons to biological tissues within about 0.1 mm to about 5 cm of the site of implantation), (2) locally enhance soluble calcium concentration (which increases bone production within about 0.1 mm to about 5 cm of the site of implantation), and (3) locally enhance soluble phosphate concentration (which also increases bone production within about 0.1 mm to about 5 cm of the site of implantation). In comparison to collagen composites containing devitalized bone matrix additives, collagen dispersions containing acidic calcium phosphates have been developed that stimulate the formation of larger explants containing bone of superior quality. As noted above, control of each of the foregoing three factors independently can be used to enhance bone production by the bone growth composition. Accordingly, acidic mineral salts other than calcium phosphate salts can be used to control pH, thereby increasing the bone morphogenic activity of bone growth proteins without providing additional calcium or phosphate. Additionally, other buffering agents (e.g., a sulfate-based buffer) or acidifying agents (e.g., lactic acid) can be used to control the local pH surrounding the composition in the absence of a calcium source, in the absence of a phosphate source, or in the absence of a calcium phosphate source. Similarly, the use of specific calcium salts (e.g., calcium citrate) which do not incorporate phosphorus can be used without regard to control of local pH or phosphate concentration. Likewise, the use of non-calcium phosphate salts (i.e., sodium phosphate salts) can be used to enhance local concentrations of phosphate ions to enhance bone morphogenic activity without specifically controlling local pH or calcium concentration. Each of these three factors (the addition of a calcium source, the addition of a phosphate source, and the control of the local pH) leads to increased bone production or growth independently of one another (see, e.g., FIGS. 10 and 11). The bone growth and production enhanced by these three factors may be increased in quantity (e.g., as evidenced by increased relative mineral mass) or quality (e.g., as evidenced by increased relative histology score) or may be increased in both quantity and quality. Furthermore, the effects on bone growth enhanced by these three factors are separately additive. Thus, the combination of any two of the three factors in the final composition will increase the production of bone above the bone growth seen with anyone of the factors independently.
  • [0056]
    A further aspect of the composition of the present invention is the acidic buffering potential in physiological solutions. More particularly, when the composition of the present invention is put into a solution, such as a bodily fluid at physiological pH (e.g., in an in vivo application) or another weakly basic solution, the composition acts to buffer the solution at an acidic pH (i.e., the pH of the composition is less than 7). Additionally, if the composition is implanted into a mammal, the composition can buffer the environment within, on, or surrounding the implanted composition to an acidic pH. More particularly, the present compositions can buffer such solutions in the surrounding environment to a pH between about 2 and about 7, preferably between about 2 and about 5, more preferably between about 2 and about 4.9, such as about 2 and 4.9, and most preferably between about 3.5 and about 4.7. Control of the pH of the compositions can be achieved by those skilled in the art using routine techniques. For example, the use of buffering agents to maintain a desired pH range is well-known. Because compositions of the present invention can be used for in vivo applications, such buffering agents desire to be biocompatible. Particularly preferred buffers are discussed in more detail below.
  • [0057]
    The pKa of calcium monophosphate is known to be about 4.2, and thus its approximate buffering range is about pH 3.2 to 5.2. A composition composed of primarily calcium monophosphate is strongly acidic (e.g., pH<4). For reference, standard pKa values of various calcium phosphate salts are approximately as follows:
    Ca(H2PO4)2 (monocalcium phosphate; MCP) pKa = 4.2
    CaHPO4.2H2O (dicalcium hydrogen phosphate; DCP) pKa = 6.5
    3CaO.P2O5.2H2O (tricalcium phosphate; TCP) pKa = 26.0
    3.33CaO.P2O5.2H2O (hydroxyapatite; HA) pKa = 57.8
    4CaO.P2O5 (tetracalcium phosphate; TTCP) pKa = 30.6
  • [0058]
    In one embodiment of the composition, each calcium phosphate salt has a pKa from about 4 to about 6.5.
  • [0059]
    In one embodiment, the calcium phosphate is selected from sparingly soluble calcium phosphates that do not excessively bind to osteoinductive proteins. A mixture of such calcium phosphates can be used. Such a calcium phosphate provides a reserve of calcium and phosphate ions which can be slowly resorbed during the healing process and does not interfere significantly with the activity of osteoinductive proteins.
  • [0060]
    Biologically compatible, sparingly soluble calcium phosphates are suitable supplements to locally increase the supply of soluble calcium [Ca2+] and phosphate [PO4 3−] ions. As shown in Table 1, calcium phosphate salts solubilize at different equilibrium ionic concentrations. Despite the fact that the local supplemented concentrations of calcium [Ca2+] and phosphate [PO4 3−] ions can vary by more than four orders of magnitude, the limited solubility of calcium phosphates ensures that only a minor fraction of the mineral is solubilized. This allows the calcium phosphate to continue to supplement the soluble mineral pool during months of expected healing.
  • [0061]
    In summary, like TCP and HA, calcium hydrogen phosphate [CaHPO4 (DICAL)] provides local concentrations of [Ca2+] and [PO4 3−] for bone healing. At the same time, DICAL's resorption rate is essentially equivalent to conventional tricalcium phosphate and hydroxylapatite BVF supplements.
    TABLE 1
    Equilibrium solubility of calcium and phosphate ions from
    several different biologically compatible calcium phosphate salts
    Equilibrium Equilibrium Insoluble fraction
    [Ca2+] [PO4 3−] [200 mg/cc]
    Plasma  2,200.0 μM  1,100.0 μM
    Ca(H2PO4)2 14,300.0 μM 28,600.0 μM 97.0000 wt. %
    (Monocal)
    CaHPO4 (DICAL)   480.0 μM   480.0 μM 99.9700 wt. %
    Ca3(PO4)2 (TCP)    1.4 μM    0.9 μM 99.9999 wt. %
    Ca5(PO4)3(OH) (HA)    2.2 μM    1.3 μM 99.9999 wt. %
    Ca4(PO4)2(OH)2 (TTCP)    28.2 μM    14.1 μM 99.9994 wt. %
  • [0062]
    In one embodiment, the calcium phosphate can be any calcium phosphate which is more than 95 wt % insoluble when 200 mg of the calcium phosphate are introduced at room temperature to 1 cc of an aqueous solution at pH 7 prior to addition of the calcium phosphate. In a further embodiment, the calcium phosphate can be any calcium phosphate which is more than 99 wt % insoluble when 200 mg of the calcium phosphate are introduced at room temperature to 1 cc of an aqueous solution at pH 7 prior to addition of the calcium phosphate. In yet a further embodiment, the calcium phosphate can be any calcium phosphate which is more than 99.9 wt % insoluble when 200 mg of the calcium phosphate are introduced at room temperature to 1 cc of an aqueous solution at pH 7 prior to addition of the calcium phosphate. Any such calcium phosphate, however, must further not excessively bind osteoinductive proteins.
  • [0063]
    Various forms of calcium phosphates are known to have different chemical affinities for endogenous osteoinductive proteins (such as BMPs). A study was performed to assess the influence of variable composition calcium phosphate salts on the soluble concentration of osteoinductive proteins. This study measured the residual concentration of soluble recombinant BMP-2 after exposing a controlled concentration aliquot to an equimolar quantity of calcium phosphate salt. According to the results in Table 2, moderately acidic calcium phosphates salts, like DICAL, preserve greater than a 50 wt % soluble concentration of rhBMP-2, i.e., do not excessively bind to osteoinductive proteins. Though not to be bound by theory, we submit the enhanced local concentration and cellular availability of bone morphogenetic proteins (BMPs) would better stimulate bone formation.
    TABLE 2
    Equilibrium solubility of osteoinductive recombinant human
    BMP-2 protein in the presence of equimolar concentrations of
    various calcium phosphates.
    [rhBMP-2]
    mg/ml [rhBMP-2] %
    Control 15.0 100%
    Ca(H2PO4)2 15.0 100%
    (MONO)
    CaHPO4 11.4 76%
    (DICAL)
    Ca3(PO4)2 (TCP) 3.5 23%
    Ca5(PO4)3(OH) (HA) 2.3 15%
  • [0064]
    As used herein, the term “osteoinductive material” refers to one or more proteins capable of inducing bone formation when implanted in a body. Suitable bone growth proteins of the present invention can be produced by purification of naturally occurring proteins (from xenograft, allograft, or autograft) or by recombinant DNA techniques. As used herein, the term recombinantly produced bone growth protein refers to the production of bone growth protein using recombinant DNA technology.
  • [0065]
    A number of naturally occurring proteins from bone or recombinant bone growth proteins have been described in the literature and are suitable. Recombinantly produced bone growth proteins have been produced by several entities. Creative Biomolecules of Hopkinton, Mass., USA produces a bone growth protein referred to as Osteoinductive Protein 1 or OP 1. Genetics Institute of Cambridge, Mass., USA produces a series of bone growth proteins referred to as Bone Morphogenic Proteins 1-8 which are described in U.S. Pat. No. 5,106,748. Purified bone growth proteins have been developed by several entities. Collagen Corporation of Palo Alto, Calif., USA developed a purified protein mixture which is believed to have osteoinductive activity and which is described in U.S. Pat. Nos. 4,774,228; 4,774,322; 4,810,691; and 4,843,063. Marshall Urist of the University of California developed a purified protein mixture which is believed to be osteoinductive and which is described in U.S. Pat. Nos. 4,455,256; 4,619,989; 4,761,471; 4,789,732; and 4,795,804. International Genetic Engineering, Inc. of Santa Monica, Calif., USA developed a purified protein mixture which is believed to be osteoinductive and which is described in U.S. Pat. No. 4,804,744. All of the foregoing patents are incorporated herein by reference.
  • [0066]
    A preferred bone growth protein of the present invention and process for making the same is described in detail in U.S. Pat. No. 5,290,763, which is incorporated herein by reference. Protein mixtures prepared in accordance with the disclosure of U.S. Pat. No. 5,290,763 are referred to herein as “Bone Protein Mixture” or “BPM.” This bone growth protein is preferred because of its high osteoinductive activity and because it is a purified bone growth protein. The Bone Protein of U.S. Pat. No. 5,290,763 exhibits osteoinductive activity at about 3 micrograms when deposited onto a suitable carrier and implanted subcutaneously.
  • [0067]
    Yet another embodiment of the preferred bone growth protein of the invention as described in U.S. Pat. No. 5,290,763 includes an osteoinductively active mixture of proteins having, upon hydrolysis, an amino acid composition of from about 20.7 to about 26.1 mole percent acidic amino acids, about 11.3 to about 15.7 mole percent hydroxy amino acids, about 37.6 to about 42.4 mole percent aliphatic amino acids, about 5.8 to about 7.9 mole percent aromatic amino acids and about 13.3 to about 19.9 mole percent basic amino acids. More particularly, the preferred bone growth protein has an amino acid composition of about 20.7 to about 26.1 (preferably about 23.4) mole percent of ASP (+ASN) and GLU(+OLN); about 11.3 to about 15.7 (preferably about 13.5) mole percent SER and THR; about 37.6 to about 42.4 (preferably about 40.0) mole percent ALA, GLY, PRO, VAL, MET, ILE, and LEU; about 5.8 to about 7.9 (preferably about 6.8) mole percent TYR and PHE; and about 13.3 to about 19.9 (preferably about 16.6) mole percent HIS, ARG, and LYS. A further embodiment of the preferred bone growth protein is a protein mixture having the approximate amino acid composition shown in Table 3.
    TABLE 3
    Amino Acid Mole Percent
    Asp 11.14
    Glu 12.25
    Ser 9.48
    Gly 8.50
    His 2.28
    Arg 7.19
    Thr 4.03
    Ala 8.05
    Pro 7.16
    Tyr 3.63
    Val 3.79
    Met 1.73
    Ile 2.75
    Leu 8.00
    Phe 3.21
    Lys 7.11
  • [0068]
    In a further embodiment, the bone growth protein of the present invention is a “TGFβ superfamily protein” which can be any protein of the art-recognized superfamily of extracellular signal transduction proteins that are structurally related to TGFβ1-5. Preferably, a TGFβ superfamily protein suitable for use in the present invention is selected from the following proteins: TGFβ1, TGFβ2, TGFβ3, bone morphogenic protein (BMP)-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, cartilage-derived morphogenic protein (CDMP)-1, CDMP-2, and/or CDMP-3.
  • [0069]
    Other bone growth proteins that can be used in the bone growth protein mixture include fibroblast growth factor (FGF)-1, BMP-1, BMP-2α, BMP-2β, BMP-3b, BMP-8b, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, TGFPβ4, TGFβ5.
  • [0070]
    The amount or dose of bone growth protein used depends on the activity of the bone growth protein and the particular application. In the case of the bone growth protein identified in U.S. Pat. No. 5,290,763, the bone growth protein is used in amounts between about 10 micrograms/gram substrate and about 10,000 micrograms/g substrate, more preferably between about 100 micrograms/g substrate and about 350 micrograms/g substrate, and more preferably between about 150 micrograms/g substrate and about 250 micrograms/g substrate.
  • [0071]
    In another embodiment, the bone growth composition can comprise between about 0.5 micromol of the acidic calcium phosphate compound per 1 microgram of total bone growth protein to about 6 micromol of the acidic calcium phosphate compound per 1 microgram of total bone growth protein.
  • [0072]
    It has been determined by the present inventor that solution pH plays a strong role in the osteoinductive performance of bone growth proteins, with acidic environments providing dramatically superior results. In other words, the bone growth protein has a second bioactivity in an acidic environment, such as that provided in its environment by the acidic substrate, greater than a first bioactivity in a neutral or basic environment.
  • [0073]
    In one embodiment, the composition includes:
  • [0074]
    about 3 parts by weight to about 10 parts by weight of a collagen:acidic calcium phosphate mineral material having an average particle size of about 125 microns to about 5000 microns, wherein the material comprises about 25 wt % to about 75 wt % of the acidic calcium phosphate mineral, the material has a porosity of about 85% to about 98%, and the collagen and the acidic calcium phosphate mineral are dehydrothermally crosslinked;
  • [0075]
    about 1 part by weight to about 20 parts by weight of collagen other than that crosslinked with the acidic calcium phosphate mineral material in the collagen:acidic calcium phosphate mineral material; and
  • [0076]
    about 2 parts by weight to about 15 parts by weight of a highly acidic calcium phosphate mineral other than that crosslinked with collagen in the collagen:acidic calcium phosphate mineral material.
  • [0077]
    The collagen:acidic calcium phosphate mineral material can have from about 33 mg acidic calcium phosphate mineral per 100 mg collagen to about 300 mg acidic calcium phosphate mineral per 100 mg collagen.
  • [0078]
    In one embodiment, the acidic calcium phosphate mineral has a Ca:PO4 ratio from about 0.5 to about 1, and the highly acidic calcium phosphate mineral has a Ca:PO4 ratio from about 0.25 to about 0.5. The acidic calcium phosphate mineral can comprise one or more of calcium hydrogen phosphate dihydrate (CaHPO4.2H2O), monocalcium phosphate (Ca(H2PO4)2), calcium pyrophosphate (2CaO.P2O5), tricalcium phosphate (3CaO.P2O5), hydroxyapatite (3.33CaO.P2O5(OH)2), tetracalcium phosphate (4CaO.P2O5), or calcium carbonate (CaCO3), and the highly acidic calcium phosphate mineral can comprise monocalcium phosphate. The pH of the composition can be tuned by the amount of the highly acidic calcium phosphate mineral used.
  • [0079]
    In further embodiments, the collagen:acidic calcium phosphate mineral material can have an average particle size of about 125 microns to about 300 microns, the material can comprise about 60 wt % to about 75 wt % of the acidic calcium phosphate mineral, and the material can have a porosity of about 94% to about 98%. In other words, the material can comprise about 150 mg acidic calcium phosphate mineral per 100 mg collagen to 300 mg acidic calcium phosphate mineral per 100 mg collagen.
  • [0080]
    In a further embodiment, the composition can comprise about 85 parts by volume to about 95 parts by volume of the collagen:acidic calcium phosphate mineral material and about 5 parts by volume to about 15 parts by volume collagen.
  • [0081]
    The composition can be further combined with a fluid, especially suitably for injection at a bone defect site. In one embodiment, the composition further comprises about 2 parts by weight to about 150 parts by weight of a fluid comprising water or an organic solvent. The fluid can include bone marrow aspirate, whole blood, plasma, platelet-rich plasma (PRP), serum, saline, water, PBS, cell culture media, or two or more thereof.
  • [0082]
    The composition can also further comprise one or more bone growth proteins as described above.
  • [0083]
    In another embodiment, the present invention relates to a method of forming a bone growth composition including combining a bone growth protein having a first bioactivity with an acidic substrate, wherein the bone growth protein has a second bioactivity when combined with the acidic substrate that is greater than the first bioactivity.
  • [0084]
    The composition of the present invention can be in a variety of different forms, such as a sponge, a paste, a fleece, or particles, among others, comprising natural materials such as collagen or chitin, among others, or synthetic materials such as PLA or PGA, among others. In a preferred embodiment, a collagen sponge is provided which contains bone growth proteins as well as calcium phosphate salts for controlling pH and providing calcium and phosphate to the local environment. An example of how to prepare such a sponge is provided below.
  • [0085]
    Another embodiment of the present invention is a novel process to produce collagen sponges for implantation which incorporate the replacement materials generally described above. In one embodiment, the products are prepared by producing a dispersion of collagen fibrils that contains either solubilized calcium salts or solubilized phosphate salts. Suitable collagen can include type I collagen, type II collagen, type III collagen, or type N collagen. In one embodiment, the collagen is from bovine tendon. The collagen dispersion is typically between about 0.5% by weight and about 20% by weight collagen, more preferably between about 1% by weight and about 10% by weight collagen, and most preferably between about 3% by weight and about 5% by weight collagen.
  • [0086]
    If the dispersion was made with a calcium salt, a phosphate salt is then added to the dispersion to heterogeneously precipitate a calcium phosphate salt directly onto the surface of the collagen fibrils. If the dispersion was made with a phosphate salt, a calcium salt is then added to the dispersion to heterogeneously precipitate a calcium phosphate salt directly onto the surface of the collagen fibrils. The interfacial adherence of the precipitate improves the mechanical rigidity and wetability of the composite sponges. The composition can be cross-linked. In one embodiment, the application of dehydrothermal collagen cross-linking techniques (e.g., 110° C., 24-72 hrs, vacuum) are well known in the art. Such cross-linking techniques result in the formation of water stable, collagen sponges of superior physical properties. Such sponges can then be loaded with bone growth protein and used for induction of bone growth in vivo. In a preferred embodiment, the products are prepared by producing a 4% (by weight) collagen dispersion that contains solubilized calcium dichloride dihydrate (CaCl2.2H2O). A solution of disodium phosphate (Na2HPO4) is added to the heterogeneously precipitate calcium hydrogen phosphate dihydrate (CaHPO4.2H2O) directly onto the surface of collagen fibrils.
  • [0087]
    In one embodiment, the composition can be formed starting with dicalcium hydrogen phosphate [CaHPO4xH2O, (DICAL)] (Sigma, St. Louis, Mo.), monocalcium phosphate [Ca(H2PO4)2 (MONOCAL)] (Sigma, St. Louis, Mo.), bovine dermal collagen, (Kensey Nash Corporation, Exton, Pa.), hydrochloric acid, and distilled, de-ionized water. After sterilization of the calcium phosphates and preparation of a 30 mM hydrochloric acid solution, a cross-linked, collagen-calcium phosphate sponge particle can be prepared.
  • [0088]
    First, a composite collagen-calcium phosphate gel dispersion (5 vol % collagen gel) can be prepared by introducing collagen and dicalcium hydrogen phosphate to one syringe, the 30 mM HCl solution to another, and mixing between the two. The dispersion can then be cast in a mold and frozen (−80° C. for at least 1 hr), followed by lyophilization/freeze-drying. The samples can then be dehydrothermally cross-linked in a vacuum oven (110° C., 48 hr) and thereafter milled and collected with −20 mesh (typically, about 0.5-1.2 micron).
  • [0089]
    Second, a high surface area (HSA), soluble collagen particle preparation can be prepared by dual-syringe mixing of collagen and sufficient 30 mM HCl to yield a 2 vol % solid dispersion. The dispersion can then be cast, frozen, and lyophilized/freeze-dried as described above. The samples can then be milled and collected with −60 mesh.
  • [0090]
    Third, the soluble HSA collagen particles (about 60 weight parts), collagen-DICAL DHT cross-linked particles (about 530 weight parts), and monocalcium phosphate powder (about 100 weight parts) can be combined to form a final dry powder.
  • [0091]
    The final dry powder can then be combined with various fluids to yield a putty or a paste, according to Table 4:
    TABLE 4
    Per 1 cc dry powder volume,
    mix the approximate
    volume of the specific
    fluids to obtain cohesive putties.
    Putty consistency
    Saline 0.4 ml
    Phosphate buffered saline 0.4 ml
    Whole blood 0.6 ml
    Paste Consistency
    Saline 1.0 ml
    Phosphate buffered saline 1.0 ml
    Whole blood 1.3 ml
  • [0092]
    Alternative processes for producing the composition of the present invention are possible.
  • [0093]
    Another process of the present invention includes implanting a composition as broadly described above into a body for induction of bone growth. The composition can be combined with a fluid, which can include bone marrow aspirate, whole blood, plasma, platelet-rich plasma (PRP), serum, saline, water, PBS, cell culture media, or two or more thereof. As noted above, most uses of the present invention are concerned with human applications. The process, however, is suitable for a wide variety of animals, such as vertebrates, such as mammals, of which humans are one example. As used herein, the term implanting refers to placing the composition of the present invention in any bone defect or other area in which it is desired to have bone grow or survive. By implanting composition, bone formation is induced by the bone growth protein. Over time, preferred calcium and phosphate materials are resorbed allowing for uniform bone formation throughout a defect area.
  • [0094]
    In another embodiment, the present invention relates to a method of promoting bone growth at a bone defect in a mammal including combining a bone growth protein having a first bioactivity with an acidic substrate, wherein the bone growth protein has a second bioactivity greater than the first bioactivity when combined with the acidic substrate; and delivering the bone growth protein to the bone defect.
  • [0095]
    The combining and delivering steps can be performed sequentially or simultaneously. The delivering step can also be considered an implanting step.
  • [0096]
    Compositions of the present invention can be used in a variety of applications whenever there is a desire to generate bone or retard bone loss. Such applications include induction of bone formation for hip replacement operations, knee replacement operations, spinal fusion procedures, repair of periodontal defects, treatment of osteoporosis, repair of bone tumor defects and repair of bone fractures and defects.
  • [0097]
    In the case of hip replacement operations, the ball and socket joint of a hip is replaced when a person's hip is not functioning properly. The ball portion of a joint is replaced by surgical removal of the ball portion from the terminus of the femur. The artificial ball portion has a functional ball end with the opposite end being a stem which is inserted into the proximal end of the femur from which the natural ball portion was removed. The stem can have a porous surface so that bone growth around the stem can anchor the stem in the femur. The product of the present invention, in particulate form, is layered, packed, or injected between the stem and the cavity in the femur in which stem is to be inserted. The socket portion of a joint is replaced by inserting an artificial socket into the natural socket. The artificial socket is sized to fit with the artificial ball. On the surface of the artificial socket which contacts the natural socket, the artificial socket can have a porous surface. The product of the present invention, in particulate form, is placed in the natural socket cavity so that upon placement of the artificial socket, the product is between the natural and artificial socket. In this manner, as bone is formed, the artificial socket is anchored in the natural socket.
  • [0098]
    Products of the present invention are also suitable for use in knee replacement operations. Knee prostheses have a femoral and a tibial component which are inserted into the distal end of the femur and the surgically prepared end of the tibia, respectively. The product of the present invention is layered, packed, or injected between the femoral and/or tibial components of the prosthesis and the respective portions of the femur and tibia. In this manner, as bone formation is induced between the prosthesis and the bones, the prosthesis becomes anchored.
  • [0099]
    Products of the present invention are also suitable for use in spinal fusion operations in which it is desired to substantially immobilize two vertebrae with respect to each other. The product can be applied, for example, between adjacent spinous and transverse processes so that upon bone formation throughout the composite material, two adjacent vertebrae are joined by fusion between the respective spinous processes and transverse processes.
  • [0100]
    In the case of periodontal defects, the product of the present invention is conformed to the defect shape. As bone growth is induced, bone fills in the defect.
  • [0101]
    In the treatment of osteoporosis, the present product is injected in existing bone to offset the effects of osteoporosis in which bone density is lost. For example, if it is determined that bone density is low in a localized area, such an injection can be made in that area.
  • [0102]
    In the treatment of bone fractures, traumatic osseous defects, or surgically-created osseous defects, the product of the present invention is layered, packed, or injected into the fracture or defect. In this manner, as bone formation is induced, the fracture or defect is treated.
  • [0103]
    In performing the method, it may be convenient to provide to the surgeon performing the delivering step to be provided with a precursor to the composition in kit form. Therefore, in another embodiment, the present invention relates to a kit for promoting bone growth at a bone defect in a mammal, comprising a bone growth protein having a first bioactivity and an acidic substrate, wherein the bone growth protein has a second bioactivity greater than the first bioactivity when combined with the acidic substrate.
  • [0104]
    The following examples are provided for the purposes of illustration and are not intended to limit the scope of the present invention.
  • EXAMPLES Example 1
  • [0105]
    This example illustrates the production and use of bone growth protein containing devices that provide equivalent or superior osteoinductive performance without the addition of demineralized bone matrix additives as biologic supplements.
  • [0106]
    This example shows the influence of the carrier vehicle on the in vitro and in vivo osteoinductivity attributable to osteoinductive growth factors. An accepted protocol to assess the osteoinductive activity of composite materials is through implantation of samples in rats. The advantages of the rat model for product evaluation include its moderate cost and an accelerated rate of bone induction. Visible evidence of mineralization appears in the implant within several days (10), with typical experiments lasting between 14 and 21 days. Osteoinductive activity is commonly evaluated using four standard test protocols: histological tissue analysis, mineral concentration via x-ray and ash weight evaluation and bone cell activity via alkaline phosphatase analysis.
  • [0107]
    This example specifically compared the osteoinductive differences between implant samples containing Bone Protein Mixture (BPM), collagen (bovine tendon type 1) and a powder of either devitalized bone matrix (DVBM) or the calcium phosphate ceramic (Ostite) [Millennium Biologix, Kingston, Canada]. Ostite is a material containing variable concentrations of calcium hydroxyapatite and silica stabilized tricalcium phosphate. Similarly to alternative calcium phosphate sources, Ostite supports the required interfacial activity of osteoblasts for bone regeneration. A unique feature of Ostite is that it has been shown to degrade only by osteoclastic resorption. Sample disks were prepared with variable composition: a) collagen (100 wt. % )/BPM and b) collagen/particle (50/50 wt. %)/BPM. The sample disks were prepared using two distinct processing techniques. In the first technique, the components were mixed in phosphate buffered saline (PBS) at a collagen ratio of 4 wt. %. The mixtures were molded into disks (h˜3 mm, d˜8 mm) and freeze dried. In the second technique, the components were mixed with dilute acetic acid (1 vol. %) to form a gel with a collagen ratio of 4 wt. %. The gels were molded into disks and freeze-dried. All disks were loaded with BPM and freeze dried according to standard protocols.
  • [0108]
    The testing protocol involved sample implantation in subcutaneous (to assess endochondral bone formation) and calvaria sites (to assess membranous bone formation). The osteoinductive responses were evaluated after 4 weeks implantation using accepted protocols for explant mass, ash weight, x-ray mineral density and histology.
  • [0109]
    Clinically, the application of bone morphogenic proteins (BMPs) and other osteoinductive growth factors are desired to assist in the surgical reconstruction of skeletal defects. BMPs are advantageous because they induce bone formation by targeting and activating undifferentiated perivascular connective tissue cells. In contrast, mitogens target and accelerate the osteoinductive activity of previously differentiated cells. Numerous advances have improved the activity of osteoinductive factors, however, their clinical application has been limited by the requirement for a superior delivery vehicle.
  • [0000]
    Procedures:
  • [0000]
    Collagen Implants:
  • [0110]
    Collagen sponge disks were prepared according to standard procedures as follows; Mix 12.0 g of 1 vol. % glacial acidic acid and 500 mg of Bovine tendon Type 1 Collagen in an inert screw cap container. Mix with a spatula as the gel begins to form, minimizing the number of trapped air bubbles. Stop mixing when the gel becomes thick. Tap gel container on bench-top to remove trapped air bubbles and cap tightly. Allow mixture to sit for at least 1 hour at room temperature.
  • [0111]
    To make disks from the collagen dispersion, place a Delrin disk mold sheet on a glass plate and press the dispersion into the holes. Remove excess dispersion with a knife or spatula. Place the molding sheet and glass plate in a freezer at −80° C. for approximately 1 hour. Remove from the freezer and allow warming for approximately 1 minute. Remove the glass plate and place the Delrin plate into a freeze drying flask. Freeze dry for a minimum of 42 hours. After drying, remove the samples from the plate, trim the edges and weigh each disk. Each disk must weigh between 6.5 to 7.3 mg to be acceptable for use.
  • [0000]
    Collagen/Powder Implants:
  • [0112]
    In an inert screw cap container, mix 600 mg of Bovine tendon Type 1 collagen with 600 mg of either Ostite powder (NP) or devitalized rat bone matrix powder (DVM). Add 14.4 g of acetic acid (1 vol. %) to prepare gel dispersions containing 4 wt. % collagen. Stir with a spatula to homogenize the mixtures and to adequately wet the components. Vibrate the mixtures on a high intensity orbital shaker to remove trapped air bubbles. Allow mixtures to sit for at least 1 hour at room temperature.
  • [0113]
    To make disks from the collagen dispersions, place a Delrin disk mold sheet on a glass plate and press the mixtures into the holes. Remove excess mixture with a knife or spatula. Place the molding sheet and glass plate in a freezer at −80° C. for approximately 1 hour. Remove from the freezer and allow warming for approximately 1 minute. Remove the glass plate and place the Delrin plate into a freeze-drying flask. Freeze dry for a minimum of 12 hours. After drying, remove the samples from the plate, trim the edges and weigh each disk. The disks must weigh between 13.0-14.6 mg to be acceptable for use.
  • [0000]
    BPM Loading:
  • [0114]
    Dilute a volume of BPM (produced as described in U.S. Pat. No. 5,290,763) with a volume of 10 mM HCl to prepare solutions of 10 mg BPM/100 ml (15 ml) and 35 mg BPM/100 ml (4.0 ml). In the Delrin loading plate, pipet 50 μl of a solution on each of the top and bottom half of a collagen sponge (n=240 (10 mg), n=48 (35 mg)). Allow disks to stand in a chamber containing a moist paper towel (to prevent drying and sponge shrinkage) at ambient temperatures for 40-60 minutes. Cover the disk holding plate with Saran Wrap and place in a −80° C. freezer for 40-60 min. Unwrap and carefully place in a freeze dryer flask. Freeze dry for a minimum of 12 hours then remove. The implant samples will respectively contain total BPM doses of 10 ng and 35 ng.
  • [0115]
    Surgical controls were used to determine the osteoinductive response in the calvaria implants due to irritation of the periosteum. A solution of 10 mM HCl was prepared and sterilized by filtration through a 0.2 mm sterile syringe filter. The solution was applied to the collagen disks in an identical manner as the BPM loaded samples and served as negative controls.
  • [0000]
    Sample Disk Implantation
  • [0116]
    The weight of each Long-Evans rat was recorded. Acceptable rats for bioassays weigh between 100 and 130 g. The animals was anesthetized with 400 μl of pentobarbital dosing solution injected i.p.
  • [0117]
    Subcutaneous sample implantation was made as follows: small (6 mm) incisions were made in the skin of the ventral or dorsal thorax. Ventral incisions were made at the base of the rib cage. A template, to be aligned with the base of the rib cage, was provided to identify constant dorsal implant locations. After incision, a pocket beneath the skin and above the incision was prepared by blunt dissection. The loaded collagen sponges were placed in the pocket, approximately 5 mm above the incision. Additional incisions and implant insertions were made and then the incisions were closed with Tedvek II 5-0 (or equivalent) sutures.
  • [0118]
    The animals were housed in compliance with the guidelines described in QC-008. The animals were checked for lesions 3-5 days post implantation. If lesions were detected or if animal death occurred before sacrifice, these results were documented.
  • [0000]
    Implantation Protocol and Analysis
  • [0119]
    The testing protocol involved subcutaneous implantation of collagen sponges (to assess endochondral bone formation) containing 10 μg BPM. The samples were placed in four subcutaneous implantation sites: the upper quadrants of a rat's abdomen and dorsal thorax [FIG. 1]. In addition, the testing protocol involved calvaria implantation of collagen sponges (to assess membranous bone formation) containing either 0 μg or 35 μg BPM. Samples of variable composition and concentration can be produced.
  • [0120]
    The osteoinductive activity of the implant is evaluated using accepted protocols for explant mass, ash weight, x-ray mineral density and histology. A total of 20 rats/composition were used. This population provided location-specific testing numbers of n=10/test for the subcutaneous assays. Normalizing the samples according to location-specific values provides a total subcutaneous sample population of n=40/test.
  • [0121]
    Three weeks post implantation, the animals (n=20) were sacrificed through CO2 asphyxiation. The weight of the host rat and each implant is immediately measured post-surgical excision. The explants are imaged with x-ray radiation to determine mineral density as a function of composition and implant location. Forty percent of the subcutaneous samples were analyzed using accepted protocols for ash weight.
  • [0122]
    The remaining subcutaneous explants were analyzed for differences in tissue quality using accepted histology protocols. The averaged results and their standard deviations were analyzed for statistical significance using ANOVA comparisons. The results are shown in FIGS. 2-5.
  • Example 2
  • [0123]
    This example illustrates the independent effects of a calcium source and a phosphate source in the present invention.
  • [0124]
    In vivo rat implantation assays were conducted to determine the effects of local supplementation of calcium, phosphate, and of both calcium and phosphate in the implanted compositions of the present invention. The implants containing a calcium source, a phosphate source or a source of both calcium and phosphate were tested and evaluated in terms of relative histology score and relative mineral mass gain. The results of these assays are shown in FIGS. 10 and 11.
  • Example 3
  • [0125]
    The effect of calcium phosphate chemical composition and microstructure (crystal structure) variations on the performance of osteoinductive proteins was evaluated using a subcutaneous rat implant model (Grossblatt, Guide for the Care and Use of Laboratory Animals. Washington D.C.: National Academy Press; 1996, 1-80; Intermedics Orthopedics/Denver, Inc. Rat Subcutaneous Bioassay: Bone Protein Assay STM-011). The advantages of the rat model for product evaluation include an accelerated rate of bone induction. Visible evidence of mineralization appears in the implant within several days (˜10), with typical experiments lasting between 14 and 21 days. The testing protocol involved implantation of porous collagen (bovine tendon Type 1, 7 mg, 96 vol. % porosity) samples containing a natural mixture of bovine, osteoinductive proteins (GFm, 10 μg). A full range of calcium phosphates was evaluated, including: monocalcium phosphate [Ca(H2PO4)2], calcium hydrogen phosphate dihydrate [CaHPO4.2H2O], calcium pyrophosphate [2CaO.P2O5], tricalcium phosphate [α-3CaO.P2O5, β-3CaO.P2O5], hydroxyapatite [3.33CaO.P5(OH)2 (polycrystalline and two amorphous compositions)], tetracalcium phosphate [4CaO.P2O5] or calcium carbonate [CaCO3 (aragonite), CaCO3 (calcite)]. Samples were implanted in four subcutaneous sites including the upper quadrants of the abdomen (sites 1, 2) and the upper quadrants of the dorsal thorax (sites 6, 7). The osteoinductive differences between controls and calcium phosphate supplemented samples [7 mg, 50 wt. %] were assessed using three standard test protocols: histological tissue analysis and mineral composition via x-ray and ash weight analysis (Intermedics Orthopedics/Denver, Inc. Histology protocol STM 009; Intermedics Orthopedics/Denver, Inc. Alkaline phophatase protocol STM 0024, 0026).
  • [0126]
    Samples were assessed in comparison to two different control sample populations, including: collagen sponges and collagen/GFm sponges supplemented with 50 wt % devitalized bone matrix (DVBM) additives. The collagen/GFm control samples were used as a reference for a baseline osteoinductive response. A calcium phosphate additive was considered detrimental if it either reduced the explant or mineral mass values or if it negatively influenced bone maturation. The composite collagen products containing devitalized bone matrix additives serve as a reference for a strongly positive osteoinductive response. These samples were prepared as an alternative for demineralized bone matrix (DBM) additives. Demineralized bone matrix provides both an ideal osteoconductive matrix for cellular invasion and bone mineralization and a pooled concentration of osteoinductive proteins. Unfortunately, the osteoinductive performance of DBM varies significantly. The composite products containing DVBM provide ideal osteoconductive benefits and controlled, uniform osteoinductive protein concentrations.
  • [0127]
    The experimental data are presented in box-whisker plot format for exploratory, nonparametric data analysis. These graphs are excellent for conveying variation information in data sets and illustrating variability between different groups of data. This information is represented within the three characteristic features of a box-whisker plots: 1) the box, 2) the horizontal line within the box and 3) the vertical lines (whiskers) that extend above and below the box.
  • [0128]
    The box encompasses the middle 50% of the data with the length of the box measuring data spread. The middle of the box represents the median or ‘middle’ value of the data set. The top of the box represents the 75th percentile, meaning that 75% of the data values fall below this value. It is mathematically equivalent to the median data value plus 0.6745 of the standard deviation. The bottom of the box represents the 25th percentile (median minus 0.6745 of the standard deviation), indicating the value which 75% of the data set exceeds. The horizontal line within the box represents the mean or average value of the data set.
  • [0129]
    The vertical lines that extend above and below the box indicate the maximum (90th percentile) and minimum (10th percentile) data values, respectively. The maximum and minimum points represent the last data values within 2.7 standard deviations of the median value. The location and length of these lines represents the distribution of data. If the mean value is found close to the center of the box and the length of the vertical lines are equivalent, it can be assumed that the data follows a normal Gaussian distribution. The data set is considered skewed if either the mean value is not centered within the box or the length of the maximum or minimum lines are unequal.
  • [0130]
    In a normal Gaussian distribution of data, outliers are defined as data values that differ from the median by more than three standard deviations. Outliers complicate statistical interpretations of data set differences because their magnitude can significantly influence the calculated mean and standard deviation. In contrast, outliers have a minimal influence on the median and quartile values used in box-whisker plots. This simplifies the identification of outliers, as identified by circles, and significantly improves statistical interpretations of data set differences.
  • [0131]
    The averaged results and their standard deviations were analyzed for statistical significance using ANOVA comparisons. ANOVA was performed without data replications turning the analysis into an expanded pool Student-T test. Statistical significance was predicted using α<0.05. Calcium phosphate compositions that had a statistically significant, negative effect on mass are italicized in the tabulated data. Compositions that had no significant influence on mass are indicated in plain text. Compositions that stimulated a statistically significant improvement in mass are indicated in bold text [Tables 5 and 6].
  • [0132]
    In comparison to the collagen controls (102.8±22.9 mg explant/11.7±3.6 mg mineral), the majority of the salts had a negligible or a detrimental effect on total explant and mineral mass [FIGS. 12, 13]. However, a bimodal increase in explant and mineral mass values was observed with moderately acidic calcium phosphate salts [CaHPO4.2H2O (+40.2 wt. % mass/+153.6 wt. % mineral), 2CaO.P2O5 (+99.6 wt. % mass, +263 wt. % mineral)] and moderately alkaline, amorphous hydroxyapatite [3.33CaO.P2O5(OH)2 (Calcitek) (+44.1 wt. % explant mass, +279.6 wt. % mineral)].
  • [0133]
    The quality and skeletal maturity of produced bone was assessed through histological microscopic analysis of thin, stained tissue sections. The subcutaneous explants were removed, fixed in formalin and histologically processed with glycol methacrylate according to standard protocols (Dickson, Glenn R.: Methods of Calcified Tissue Preparation. Elsevier, 1984). Thin sections (4 μm) from the explant midlines were obtained with a microtome. One section was stained with hematoxylin & eosin (H&E) and one was stained with toluidine blue to highlight important cellular details. The H&E sections were counterstained with silver nitrate (Von Kossa technique) to highlight mineralized tissue components. The histological sections were scored for quality and maturity using a scoring system, outlined in Table 7, previously developed by Sulzer Biologics according to STM-021.
  • [0134]
    Using the described protocols, the influence of the various additives on histological quality was determined. The average histology score and the inter-animal standard deviation values are tabulated in the first two columns of Table 8. The relative differences in histology score, observed between experimental and control samples within a single rat (intra-animal difference), are included in the last four columns of Table 8. The magnitude and range of total and relative histological scores is graphically represented in the box plots of FIG. 14.
    TABLE 5
    Average (inter-animal) and relative (intra-animal) explant mass
    for implants supplemented with various calcium phosphates.
    Average Explant Mass
    Average Explant
    Mass Direct Comparison Averages
    [mg] ±SD N [mg] ±SD Δwt. % ±SD N
    Control 102.8 22.9 235
    DVBM 142.8 46.0 290 178.9 27.8 +66.8% 39.4% 40
    Ca(H2PO4)2 (MCP) 104.4 29.2 90 95.3 31.6 −6.4% 26.2% 30
    CaHPO4.2H2O 130.7 34.2 185 129.8 29.2 +40.2% 32.9% 40
    (DCP)
    2CaO.P2O5.2H2O (CP) 126.2 49.5 25 170.3 43.7 +99.6% 27.1% 10
    3CaO.P2O5 (α- 39.5 31.9 35 58.7 28.3 −42.9% 26.4% 20
    TCP)
    3CaO.P2O5 (β- 80.1 43.4 45 71.6 40 −26.3% 33.6% 20
    TCP)
    3.33CaO.P2O5 (HA- 113.5 32.2 20 124.7 43.1 +4.5% 37.2% 10
    px)
    3.33CaO.P2O5 (HA- 129.9 60.3 30 120.3 32.2 +0.3% 29.6% 15
    am)
    3.33CaO.P2O5 (HA- 117.9 36.3 30 140.6 30.2 +44.1% 25.0% 10
    am)
    4CaO.P2O5 54.8 30.9 20 70.0 38.3 −46.2% 39.2% 10
    (TTCP)
    CaCO3 69.4 30.7 40 88.6 32.6 −27.3% 26.0% 10
    (aragonite)
    CaCO3 67.4 27.9 40 73.1 24.0 −28.0% 20.2% 10
    (calcite)
  • [0135]
    TABLE 6
    Average (inter-animal) and relative (intra-animal) mineral mass
    for implants supplemented with various calcium phosphates.
    Average Mineral Mass
    Average Mineral
    Mass Direct Comparison Averages
    [mg] ±SD n [mg] ±SD Δwt. % ±SD n
    Control 11.7 3.6 74
    DVBM 16.4 5.4 115 16.9 4.5 +50.4% 20.2% 8
    Ca(H2PO4)2 16.0 4.6 26 14.2 6.0 +50.2% 27.5% 8
    (MCP)
    CaHPO4.2H2O 18.0 4.5 73 16.4 3.2 +53.6% 28.3% 16
    (DCP)
    2CaO.P2O5.2H2O (CP) 20.8 10.0 10 31.5 2.4 +163.0% 29.5% 4
    3CaO.P2O5 (α- 6.5 7.7 12 9.4 8.1 −28.3% 28.6% 8
    TCP)
    3CaO.P2O5 (β- 8.1 6.1 4 5.7 2.0 −31.6% 11.1% 4
    TCP)
    3.33CaO.P2O5 (HA- 19.8 8.2 8 21.9 10.1 +74.3% 25.3% 4
    px)
    3.33CaO.P2O5 (HA- 26.5 6.7 12 27.1 2.0 +95.6% 21.9% 4
    am)
    3.33CaO.P2O5 (HA- 29.4 12.1 12 30.4 5.8 +179.6% 12.7% 3
    am)
    4CaO.P2O5 7.7 6.1 7 10.3 8.8 −43.5% 28.3% 4
    (Tetra)
    CaCO3 10.4 5.4 28 14.5 4.2 +3.8% 26.7% 4
    (aragonite)
    CaCO3 7.9 5.2 27 8.1 3.0 −3.2% 28.5% 4
    (calcite)
  • [0136]
    The collagen control samples produced explants with an average histology score of approximately 2.2 (±0.6). The majority of samples resulted in histology scores of 2.0 or 3.0 with a small fraction obtaining scores of 1.0. The collagen control samples with DVBM produced explants with an average histology score of 2.8 (±0.8). The majority of samples resulted in histology scores of 2.0 or 3.0 with a small fraction obtaining scores of 1.0 and 4.0.
  • [0137]
    According to statistical analysis (Student T-test), the addition of DVBM significantly enhances osteoinductive performance (α<0.05). The magnitude of the osteoinductive enhancement is represented in the lower box plot of FIG. 15. This plot includes intra-animal, relative histological score comparisons between the collagen and collagen DVBM controls. The intra-animal comparison indicates that the DVBM additives enhance histological scores by an average of +33.3% wt. % (±19.8 wt. %) with the majority of the improvements ranging between +0% and +50%.
  • [0138]
    In contrast to the previous results, only acidic calcium phosphate additives produced explants with histological scores equivalent and superior to that observed with the addition of DVBM. Statistically superior improvements in histological score were observed with monocalcium phosphate [Ca(H2PO4)2, Monocal] (+9.9 wt. %), calcium hydrogen phosphate dihydrate [CaHPO4.2H2O, DICAL] (+53.6 wt. %) and calcium pyrophosphate [2CaO.P2O5, Pyro] (+163 wt. %) additives. Statistically significant reductions were observed in histological score for all other salt compositions.
  • [0139]
    The experimental data indicates that osteoinductive performance is hindered with calcium phosphate salts of high (>2 Ca/P) calcia (CaO) content. In addition, the Ca/P ratio in the calcium phosphate salt directly correlates with its pH buffering potential, with high ratios being strongly alkaline. Monocalcium phosphate [Ca(H2PO4)2] is highly acidic (pH˜2). Dicalcium hydrogen phosphate and calcium pyrophosphate are moderately acidic (pH˜5.5). The neutral transition point (pH˜7) is located with tricalcium phosphate compositions. Hydroxyapatites are moderately alkaline (pH˜8). Tetracalcium phosphate and calcium carbonates are highly alkaline (pH˜10-11). This information indicates that osteoinductive performance is hindered with neutral and alkaline pH buffering additives or calcium phosphate salts having a high calcium content.
  • [0140]
    The effect of pH on bone quality and maturity is clearly demonstrated in the photomicrographs included in FIG. 15. The photomicrographs show the bone pattern on the periphery of the explanted material (2× magnification). Histological sections were selected from samples that matched both the average mass and the average histology score for each test group. The sample and its intra-animal collagen control are presented side-by-side.
  • [0141]
    In the Hematoxylin and eosin stained samples (FIG. 15, left), practically all cytoplasmic structures and intercellular substances are stained various shades of pink. The addition of silver nitrate (Von Kossa technique) stains all mineral black, making it simple to detect mineralized tissue. Although this simplifies assessments of mineralization patterns, it does not aid in distinguishing between new bone, mineralized cartilage, residual calcium phosphate additives and calcified carrier. Induced bone is distinguished from other mineralized tissues only by the combined presence of osteoid matrix seams (bright pink) and layered osteoblasts. Mature bone is represented by a continuous and thick cortical rim, lined with a continuous seam of osteoid matrix and active osteoblasts. Marrow quality is also easily assessed with this staining technique since the nuclear structures are stained dark purple or blue. Mature marrow is represented by samples that contain high concentrations of hemopoietic granulocytes (stained dark blue) and fat cells (adipocytes). The location and concentration of fat cells is represented by solubilized white voids.
  • [0142]
    The toluidine blue tissue stained samples were used to identify cartilage tissue. Cartilage tissue is stained light to deep purple, depending on the local concentration of proteoglycans. Mature cartilage contains a high concentration of proteoglycans. This stain is also useful for visualizing the number and activity of osteoblasts (Ob) and osteocytes (Oc) which are stained dark blue. Bone (B) appears lavender.
  • [0143]
    It is clearly observed that the acidic calcium phosphates universally stimulated the amount of bone formation (section diameter) and the depth of bone mineralization (bone staining content). Collagen samples supplemented with calcium hydrogen phosphate dihydrate [CaHPO4.2H2O] matched the cortical rim bone quality observed in collagen/DVBM controls. The perimeters for samples containing monocalcium phosphate and calcium pyrophosphate were comparatively reduced in maturity but were greater than control samples. Improvements in marrow quality were realized with each acidic calcium phosphate additive, with the samples supplemented with calcium hydrogen phosphate being the most mature. These samples contained high density concentrations of hemopoeitic granulocytes, red blood cell sinuses, and small adipocyte concentrations characteristic of mature bone.
  • [0144]
    Despite the increase in mass values, a negative effect on bone ossicle maturation, characterized by reduced cellular activity and dystrophic mineralization, was observed with hydroxyapatite and other alkaline calcium phosphate salts. In contrast, the samples supplemented with moderately acidic calcium phosphate salts enhanced bone maturation as well as the positive influences noted above. In fact, the histological qualities for samples containing calcium hydrogen phosphate dihydrate [CaHPO4.2H2O] additives were superior to that observed with devitalized bone matrix (DVBM) additives.
  • [0145]
    As indicated by the above described results, collagen dispersions containing calcium hydrogen phosphate dihydrate salts [CaHPO4.2H2O] stimulated the performance of osteoinductive proteins resulting in bone of increased mass and superior bone maturity. Based on this evidence, the salt and other acidic calcium salts can be used as an alternative for demineralized bone additives. This substitution should provide significant economic savings, eliminate potential allograft disease transfer and provide more reproducible and superior clinical results as a bone void filler or autogeneous graft extender.
    TABLE 7
    Histological scores and sample requirements.
    Histological
    Score Sample criteria
    0 No residual implanted sample found.
    Section shows no silver stained deposits or those deposits are associated with
    acellular events.
    Explants are generally small, soft and avascular.
    1 Focal areas of silver stained mineralized tissues are of cellular origin. This
    may include mineralized cartilage as well as mineralized osteoid matrix.
    Silver stained areas are randomly located throughout the explant, and
    typically encompass less than 50% of the explant.
    Generally small
    2 Silver stained areas are mineralized cartilage or very early woven bone.
    Osteoblasts appear in rows of only about 6 to 10 cells.
    If osteoid is present, it is generally present on less than 10% of the
    mineralizing tissue in the section.
    Small areas of hematopoietic marrow elements may be visible (generally
    sinusoids containing red blood cells).
    3 Sheets of active osteoblasts, (e.g., cells are plump and cuboidal or polygonal)
    generally consisting of 10 or more cells, appear in less than 50% of the active
    mineralized portion. They are generally not continuous.
    Bone associated with osteoblasts is generally woven, containing some
    osteocytes.
    Woven bone appears at outer regions of explant and may have breaks of
    fibrous tissue or mineralized cartilage <10% of surface.
    Some hematopoietic marrow elements may be visible. (Hemopoietic cords
    and sinusoids containing red blood cells).
    4 Mineralized tissue at the periphery is generally not woven, but a mature band
    containing lamellar bone.
    Mature bone is associated with continuous osteoblast surfaces in at least 50%
    of bony area.
    Osteoid contains active osteoblasts and a visible osteoid matrix.
    Evidence of bone marrow through presence of granulocytes, hemopoietic
    cords and sinusoids is common.
    Evidence of osteoclastic re-adsorption.
    5 Solid rim of mature bone with few breaks around outer edge.
    Mature bone contains osteocytes in organized patterns.
    Mature bone contains wide dark staining (in TBO stain) osteoid.
    Osteoid seams are continuous; very thick with osteoblasts.
    Bone marrow contains hemopoietic cords packed with cells, granulocytes,
    sinusoids and adipocytes.
    Trabecular bone in marrow is reabsorbing and may appear as focal areas with
    little branching.
    Explant center may contain mature woven bone or be infarcted and largely
    acellular.
    Strong presence of osteoclasts and/or lacunae.
  • [0146]
    TABLE 8
    Average (inter-animal) and relative (intra-animal) histological
    scores for implants supplemented with various calcium
    phosphates.
    Average Histology Score
    Average Mineral
    Mass Direct Comparison Averages
    [0-5] ±SD n [0-5] ±SD [%] ±SD n
    Control 2.2 0.6 123
    DVBM 2.8 0.8 156 3.0 0.3 +33.3% 19.8% 18
    Ca(H2PO4)2 2.2 0.8 48 1.9 0.6 +9.9% 19.8% 18
    (MCP)
    CaHPO4.2H2O 2.9 0.8 111 2.5 0.7 +39.1% 23.2% 24
    (DCP)
    2CaO.P2O5.2H2O (CP) 2.3 0.6 15 2.3 0.5 +11.1% 22.8% 6
    3CaO.P2O5 (α- 1.1 0.4 21 1.3 0.5 −35.1% 27.4% 12
    TCP)
    3CaO.P2O5 (β- 1.3 0.5 9 1.3 0.5 −23.9% 22.2% 6
    TCP)
    3.33CaO.P2O5 (HA- 1.3 0.5 12 1.2 0.4 −46.7% 27.4% 6
    am)
    3.33CaO.P2O5 (HA- 1.4 0.5 18 1.7 0.5 −20.0% 27.4% 6
    am)
    3.33CaO.P2O5 (HA- 1.4 0.5 18 2.0 0.0 −26.7% 18.3% 6
    px)
    4CaO.P2O5 1.0 0.0 12 1.0 0.0 −36.1% 18.7% 6
    (TTCP)
    CaCO3 1.0 0.0 24 1.0 0.0 −63.9% 6.8% 6
    (aragonite)
    CaCO3 1.0 0.0 24 1.0 0.0 −58.3% 9.1% 6
    (calcite)
  • Example 4
  • [0147]
    A paste was made comprising (i) about 90 parts by volume dehydrothermally-crosslinked collagen:dical particles (about 66 wt % dical) having particle sizes of 125-300 mm and 96% porosity; (ii) about 10 parts by volume soluble collagen; (iii) monocalcium phosphate; and (iv) about 100 parts by volume water. The monocalcium phosphate was included for pH control and the amount varied, with greater amounts leading to lower paste pH. Generally, the amount of monocalcium phosphate was about 2-10 wt % relative to components (i)-(iii), i.e., not including the weight of water. Generally, sufficient monocalcium phosphate was added to yield pH values of the paste from about 4.5 to 4.9. The dehydrothermal crosslinking was performed at about 110° C. for about 48 hr.
  • [0148]
    The high porosity of component (i) was chosen to encourage high rate and depth of cellular penetration into the paste. In essence, the particles (i) act as extrinsic bone nucleation sites throughout the entire mass.
  • [0149]
    The relatively small concentration of soluble collagen (ii) was chosen to allow for the development of a cohesive, taffy-like paste consistency. The cross-linked collagen:dical particles are completely insoluble and lack cohesion in water or marrow. In contrast, the addition of soluble collagen allows the formation of a collagen gel. Collagen forms highly viscous gels near its isoelectric point (pH 4-5.5). Simple, short-term pH control causes the collagen to solubilize and gel, trapping the cross-linked collagen particles in a cohesive, pliable mass.
  • [0150]
    Monocalcium phosphate (iii) was selected as a salt for temporary acidic pH control in the paste. Its use, in comparison to alternatives, results in dramatically superior improvements in stimulated bone quantity and histological quality. These results were also supported in prior sponge optimization research. The pH effect was temporary primarily as a result of the solubility of monocalcium phosphate in body fluids.
  • [0151]
    The pastes generated according to this example were tested in the rat model described in Example 3.
  • [0152]
    The effect of initial pH of the paste on explant mass and mineral mass is shown in FIG. 16. The effect of initial pH of the paste on the histology score is shown in FIG. 17.
  • [0153]
    The results in FIG. 16 clearly demonstrate that pH has a significant effect on total explant and mineral mass. The results in FIG. 17 also indicate that within the tested range acidic pH values have little influence on histological bone maturity. It should be emphasized when reviewing these results that, in comparison to reference controls with equivalent inductive growth factor doses, the paste formulations yield histologically superior explants with average bone masses around 250 mg, which corresponds to a 400% improvement in bone mass induction.
  • [0154]
    With respect to FIGS. 2-5, the osteogenic effects of collagen disks containing various calcium phosphate salt compositions and bone growth protein (BMP) were assessed based on explant mass (FIGS. 2A-B), histology score (FIGS. 3A-B), mineral concentration (FIGS. 4A-B) and mineral mass (FIGS. 5A-B). As comparatives, some conventional, commercially available osteoinductive compositions (ProOsteon 200R-acidic, ProOsteon 200R-neutral, Ostite C1-C3, GB9N and Bioglass) were similarly tested. Various osteoinductive compositions (first column in FIGS. 2B-5B) were formed into disks together with collagen and BMP, and tested (“CPB” in FIGS. 2B-5B). A control composition comprising collagen and BMP was also tested with each of the above-described samples, and its performance is reported under the heading “CB” in FIGS. 2B-5B).
  • [0155]
    Similarly, with respect to FIGS. 6-9, the same CP/collagen/BMP disks were again tested for osteogenic performance ((“CPB” in FIGS. 6B-9B) and compared to the performance of control disks containing devitalized bone matrix instead of collagen (“CDB” in FIGS. 6B-9B).
  • [0156]
    Acidic mineral salts other than calcium phosphate salts can be used to control pH, e.g., sulfate-based buffer, lactic acid, calcium citrate, sodium phosphate, and others (page 13, line 22-page 14, line 9). As shown in FIG. 10, implanting a non-calcium phosphate/collagen/BMP composition of pH ranging from 4.5 to 6.5, supplemented with calcium ion, improved the histology score (˜130-135%), compared to the histology score obtained with the unsupplemented composition (100%). On the other hand, a phosphate-supplemented composition of pH ranging from 4.5 to 6.5 did not alter the histology score significantly. Simultaneous supplementation of the composition with both phosphate and calcium ions resulted in significant improvements in bone maturity or histology (FIG. 10) and additional bone mass improvements (FIG. 11).
  • [0157]
    The in vivo performance of osteogenic proteins is influenced by the presence in the osteogenic composition of essential bone components (collagen, calcium, phosphate) and solution pH. Only acidic calcium phosphate additives, however, produced explants with histological scores equivalent and superior to that observed with the addition of devitalized bone matrix (CDB). Statistically superior improvements in histological score were observed with the monocalcium phosphate-based compositions [Ca(H2PO4)2, MCP], calcium hydrogen phosphate dihydrate-based compositions [CaHPO4.2H2O, DCP], and calcium pyrophosphate-based compositions [2CaO.P2O5, CP]. Statistically significant reductions were observed in histological score for all other salt-based compositions tested. Osteogenic performance is hindered with calcium phosphate salts of high (>2 Ca/P) calcia (CaO) content. The Ca/P ratio in the calcium phosphate salt directly correlated with its pH buffering potential (i.e., pKa), with high ratios being strongly alkaline. Monocalcium phosphate [Ca(H2PO4)2] is highly acidic (pH˜2). Dicalcium hydrogen phosphate and calcium pyrophosphate are moderately acidic (pH˜5.5). The neutral transition point (pH˜7) is located with tricalcium phosphate compositions. Hydroxyapatites are moderately alkaline (pH˜8). Tetracalcium phosphate and calcium carbonates are highly alkaline (pH˜10-11). Osteogenic performance is hindered with neutral and alkaline additives.
  • [0158]
    In conclusion, regarding the influence of composition pH and soluble ion supplementation on osteogenic bone formation, first, the pH of the composition, and thus temporary local pH control of the initial bone growth environment, could be exploited to significantly increase explant and mineral mass values. Explant mass (FIGS. 2A,B and 6A,B), mineral concentration (FIGS. 4A,B and 8A,B) and mineral mass (FIGS. 5A,B and 9A,B) values were appreciably enhanced with either hydroxyapatite or with CP or DCP-based compositions (i.e., moderately alkaline (pH˜8.5) or moderately acidic (pH˜4.5-6.5) salt components).
  • [0159]
    Second, statistically significant improvements in bone maturity or histology score (FIGS. 3A,B and 7A,B) were realized with the combined use of moderately acidic compositions containing both soluble calcium and phosphate ions and BMP, compared to hydroxyapatite-based compositions with BMP, on either collagen (FIGS. 3A,B) or devitalized bone matrix (FIGS. 7A,B). In contrast, moderately alkaline pH compositions (i.e., the hydroxyapatite-based compositions) hindered bone maturation and significantly reduced cellular activity (FIGS. 3A,B and 7A,B).
  • [0160]
    Clearly, some of the results are contrary to conventional thinking at the time the subject invention was conceived and reduced to practice. The fact that the majority of the calcium phosphate additives had no effect, or had a negative effect on explant mass contradicts the hypothetical benefits that calcium and phosphate ion supplementation would reasonably have been expected to offer. Based on the available knowledge in this field at the time of the invention, it was originally hypothesized that the clinical performance of osteogenic proteins could be enhanced by supplementing the local availability of essential bone components (collagen, calcium, phosphate). However, if local supplementation were beneficial, one of skill in this field would have expected that improvements in explant mass would have been observed with every calcium phosphate additive that was tested. Furthermore, variations in explant mass improvements would have been expected due to basic solubility, pH and compositional differences [Ca/P ratio]. However, it is shown herein that both acidic composition and Ca/PO4 ion supplementation can enhance and improve osteoinductive growth factor-induced bone formation independently. It was unexpected that the moderately acidic DCP and CP-based compositions significantly enhanced explant and mineral mass values, compared to the other compositions tested. Our observation that the majority of the calcium phosphate additives had no effect, or had a negative effect on explant mass is contrary to the expected benefits of supplementation with calcium and phosphate ion.
  • Example 5
  • [0161]
    A variety of sparingly soluble calcium phosphate salts, [Cax(PO4)y] were used to assess the influence of differences in local, soluble [Ca2+] and [PO4 3−] ion concentrations and in chemical BMP affinity as demonstrated by bone formation in a small animal model.
  • [0162]
    The effect of calcium phosphate chemical composition and microstructure (crystal structure) variations on the performance of osteoinductive proteins was evaluated using a subcutaneous rat implant model (FIG. 1). This model has an accelerated rate of bone induction with visible evidence of mineralization appearing in the implant within 1-2 weeks (˜10 days), with typical experiments lasting between 14 and 21 days. Osteogenic activity is commonly evaluated using three standard test protocols: histological tissue analysis and mineral composition via x-ray and ash weight analysis.
  • [0163]
    The testing protocol involved implantation of porous collagen (bovine tendon Type 1, 7 mg, 96 vol. % porosity) samples containing a natural mixture of bovine, osteoinductive proteins (BMPs, 10 μg). A full range of calcium phosphates was evaluated, including: monocalcium phosphate [Ca(H2PO4)2], calcium hydrogen phosphate [CaHPO4], calcium pyrophosphate [2CaO.P2O5], tricalcium phosphate [α,β-Ca3(PO4)2], hydroxylapatite [Ca5(PO4)3(OH)], tetracalcium phosphate [Ca4(PO4)2(OH)2] or calcium carbonate [CaCO3]. The experimental results were used to identify a synthetic additive for collagen to improve its osteoinductive performance.
  • [0164]
    The effect of variable calcium phosphate compositions on bone quality and maturity is clearly demonstrated in the photomicrograph shown in FIG. 15. The photomicrographs show the bone pattern on the periphery of the explanted material at 2× magnification. Histological sections were selected from samples that matched both the average mass and the average histology score for each test group. The sample and its intra-animal collagen control are presented side-by-side.
  • [0165]
    In the hematoxylin and eosin stained samples, practically all cytoplasmic structures and intercellular substances are stained various shades of pink. The addition of silver nitrate (Von Kossa technique) stains all mineral black making it simple to detect mineralized tissue. Although this simplifies assessments of mineralization patterns, it does not aid in distinguishing between new bone, mineralized cartilage, residual calcium phosphate additives and calcified carrier. Induced bone is distinguished from other mineralized tissues only by the combined presence of osteoid matrix seams (bright pink) and layered osteoblasts. Mature bone is represented by a continuous and thick cortical rim, lined with a continuous seam of osteoid matrix and active osteoblasts. Marrow quality is also easily assessed with this staining technique since the nuclear structures are stained dark purple or blue. Mature marrow is represented by samples that contain high concentrations of hemopoietic granulocytes (stained dark blue) and fat cells (adipocytes). The location and concentration of fat cells is represented by solubilized white voids.
  • [0166]
    The toluidine blue tissue stained samples were used to identify cartilage tissue. Cartilage tissue is stained light to deep purple, depending on the local concentration of proteoglycans. Mature cartilage contains a high concentration of proteoglycans. This stain is also useful for visualizing the number and activity of osteoblasts (Ob) and osteocytes (Oc) which are stained dark blue. Bone (B) appears lavender; however residual calcium phosphate salts and other mineralized tissues are equally stained. Marrow elements are difficult to distinguish with this stain.
  • [0167]
    It is clearly observed that the moderately acidic calcium phosphate salts universally stimulated the amount of bone formation (section diameter) and the depth of bone mineralization (bone staining content). Collagen samples supplemented with calcium hydrogen phosphate dihydrate [CaHPO4] were the only samples that match the cortical rim bone quality observed in collagen/DVBM controls. The perimeters for samples containing monocalcium phosphate and calcium pyrophosphate were comparatively reduced in maturity. Although improvements in marrow quality were realized with each moderately acidic calcium phosphate additive, the samples supplemented with calcium hydrogen phosphate were the most mature. These samples contained high density concentrations of hemopoeitic granulocytes, red blood cell sinuses, and small adipocyte concentrations characteristic of mature bone.
  • [0168]
    In contrast, it is observed that the addition of neutral and alkaline calcium phosphate salts significantly inhibits bone formation. The histological quality of the samples supplemented with tricalcium phosphate, hydroxyapatite, tetracalcium phosphate, or calcium carbonate are comparatively reduced. Cellular content and cellular activity correspondingly decreased within samples supplemented with calcium phosphates of increased alkalinity. In the histological sections provided, few areas of active cellular activity are observed. Although the representative sections confirm the experimental observations of increased explant and mineral mass by the differences in sample size and mineral staining, the mineral is of extremely poor quality. The mineral content predominantly includes dystrophically mineralized carrier collagen.
  • [0169]
    The experimental evidence demonstrates that synthetic bone void fillers supplemented with calcium hydrogen phosphate [CaHPO4 (DICAL)] enhances both the quantity and histological quality of bone produced. Moderately acidic microenvironments improve protein-stimulated osteoinduction in several different ways. First, an acidic microenvironment can enhance the rates of protein solubilization and protein release from collagen. The resultant increase in local concentration and cellular availability of bone morphogenetic proteins (BMPs) could explain the observed enhancements in bone formation and bone quality. Local pH may also affect protein conformation or cellular activity.
  • [0170]
    Calcium phosphate compositions with alkaline buffering potentials hinder protein stimulated osteogenic bone formation by two mechanisms. First, bone morphogenetic proteins are insoluble and precipitate in alkaline solutions. The alkaline calcium phosphate additives may precipitate a significant fraction of the inductive proteins and inhibit their osteogenic capabilities. Second and more importantly, alkaline environments initiate the direct precipitation of soluble calcium and phosphate ions. It is likely the alkaline additives cause the serum calcium and phosphate ions to immediately precipitate as apatite onto collagen. If the BMPs simultaneously precipitate within these dystrophic crystals, they would be unavailable to cells until after osteoclastic resportion of the mineralized deposits. The general appearance and lack of cellular activity and the enhanced dystrophic mineral content supports this theory.
  • [0171]
    While various embodiments of the present invention have been described in detail, it is apparent that modifications and adaptations of those embodiments will occur to those skilled in the art. It is to be expressly understood, however, that such modifications and adaptations are within the scope of the present invention, as set forth in the following claims.

Claims (50)

1. A bone growth composition, comprising:
a bone growth protein having a first bioactivity; and
an acidic substrate;
wherein the bone growth protein has a second bioactivity greater than the first bioactivity when combined with the acidic substrate.
2. The bone growth composition of claim 1, wherein the bone growth protein is selected from transforming growth factor β (TGFβ)1, TGFβ2, TGFβ3, bone morphogenic protein (BMP)-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, cartilage-derived morphogenic protein (CDMP)-1, CDMP-2, or CDMP-3.
3. The bone growth composition of claim 1, wherein the acidic substrate comprises collagen, fibrin, alginate, or a mixture of two or more thereof.
4. The bone growth composition of claim 1, wherein the acidic substrate comprises a calcium source and a phosphate source.
5. The bone growth composition of claim 4, wherein the calcium source and the phosphate source are calcium hydrogen phosphate dihydrate, monocalcium phosphate, calcium pyrophosphate, or a mixture of two or more thereof.
6. The bone growth composition of claim 1, further comprising a fluid selected from the group consisting of marrow, serum, whole blood, saline, and water.
7. A bone growth composition, comprising
a bone growth protein; and
an acidic substrate comprising an acidic calcium phosphate compound;
wherein the bone growth composition comprises between about 0.5 μmol and about 6 μmol of the acidic calcium phosphate compound per 1 μg of total bone growth protein.
8. The bone growth composition of claim 7, wherein the bone growth composition comprises between about 1 μmol and about 5 μmol of the acidic calcium phosphate compound per 1 μg of total bone growth protein.
9. The bone growth composition of claim 8, wherein the bone growth composition comprises between about 2 μmol and about 4 μmol of the acidic calcium phosphate compound per 1 μg of total bone growth protein.
10. The bone growth composition of claim 7, wherein the bone growth protein is selected from transforming growth factor β (TGFβ)1, TGFβ2, TGFβ3, bone morphogenic protein (BMP)-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, cartilage-derived morphogenic protein (CDMP)-1, CDMP-2, or CDMP-3.
11. The bone growth composition of claim 7, wherein the acidic substrate comprises collagen, fibrin, alginate, or a mixture of two or more thereof.
12. The bone growth composition of claim 7, wherein the acidic calcium phosphate compound is calcium hydrogen phosphate dihydrate, monocalcium phosphate, calcium pyrophosphate, or a mixture of two or more thereof.
13. A method of promoting bone growth at a bone defect in a vertebrate, comprising:
delivering a bone growth protein having a first bioactivity to the bone defect; and
delivering an acidic substrate to the bone defect, wherein the bone growth protein has a second bioactivity greater than the first bioactivity when combined with the acidic substrate.
14. The method of claim 13, wherein the bone growth protein is selected from transforming growth factor β (TGFβ)1, TGFβ2, TGFβ3, bone morphogenic protein (BMP)-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, cartilage-derived morphogenic protein (CDMP)-1, CDMP-2, or CDMP-3.
15. The method of claim 13, wherein the acidic substrate comprises collagen, fibrin, alginate, or a mixture of two or more thereof.
16. The method of claim 13, wherein the acidic substrate comprises a calcium source and a phosphate source.
17. The method of claim 16, wherein the calcium source and the phosphate source are calcium hydrogen phosphate dihydrate, monocalcium phosphate, calcium pyrophosphate, or a mixture of two or more thereof.
18. The method of claim 13, wherein the bone growth protein and the acidic substrate are delivered simultaneously to the bone defect.
19. A method of forming a bone growth composition, comprising:
combining a bone growth protein having a first bioactivity with an acidic substrate, wherein the bone growth protein has a second bioactivity greater than the first bioactivity when combined with the acidic substrate.
20. The method of claim 19, wherein the bone growth protein is selected from transforming growth factor β (TGFβ)1, TGFβ2, TGFβ3, bone morphogenic protein (BMP)-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, cartilage-derived morphogenic protein (CDMP)-1, CDMP-2, or CDMP-3.
21. The method of claim 19, wherein the acidic substrate comprises collagen, fibrin, alginate, or a mixture of two or more thereof.
22. The method of claim 19, wherein the acidic substrate comprises a calcium source and a phosphate source.
23. The method of claim 22, wherein the calcium source and the phosphate source are calcium hydrogen phosphate dihydrate, monocalcium phosphate, calcium pyrophosphate, or a mixture of two or more thereof.
24. The method of claim 19, wherein the bone growth protein and the acidic substrate are combined prior to delivery of the composition to a patient.
25. A kit for promoting bone growth at a bone defect in a mammal, comprising:
a bone growth protein having a first bioactivity and an acidic substrate, wherein the bone growth protein has a second bioactivity greater than the first bioactivity when combined with the acidic substrate.
26. The kit of claim 25, wherein the bone growth protein is selected from transforming growth factor β (TGFβ)1, TGFβ2, TGFβ3, bone morphogenic protein (BMP)-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, cartilage-derived morphogenic protein (CDMP)-1, CDMP-2, or CDMP-3.
27. The kit of claim 25, wherein the acidic substrate comprises collagen, fibrin, alginate, or a mixture of two or more thereof.
28. The kit of claim 25, wherein the acidic substrate comprises a calcium source and a phosphate source.
29. The kit of claim 28, wherein the calcium source and the phosphate source are calcium hydrogen phosphate dihydrate, monocalcium phosphate, calcium pyrophosphate, or a mixture of two or more thereof.
30. The kit of claim 25, wherein the bone growth protein and the acidic substrate are included in a common package.
31. The bone growth composition of claim 1, produced by the process comprising:
combining the bone growth protein with an acidic substrate, wherein the bone growth protein has a second bioactivity greater than the first bioactivity when combined with the acidic substrate.
32. The bone growth composition of claim 31, wherein the bone growth protein is selected from transforming growth factor β (TGFβ)1, TGFβ2, TGFβ3, bone morphogenic protein (BMP)-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, cartilage-derived morphogenic protein (CDMP)-1, CDMP-2, or CDMP-3.
33. The bone growth composition of claim 31, wherein the acidic substrate comprises collagen, fibrin, alginate, or a mixture of two or more thereof.
34. The bone growth composition of claim 31, wherein the acidic substrate comprises a calcium source and a phosphate source.
35. The bone growth composition of claim 31, wherein the bone growth protein and the acidic substrate are combined ex vivo.
36. The bone growth composition of claim 34, wherein the calcium source and the phosphate source are calcium hydrogen phosphate dihydrate, monocalcium phosphate, calcium pyrophosphate, or a mixture of two or more thereof.
37. A composition, comprising:
about 3 parts by weight to about 10 parts by weight of a collagen:acidic calcium phosphate mineral material having an average particle size of about 125 microns to about 5000 microns, wherein the material comprises about 25 wt % to about 75 wt % of the acidic calcium phosphate mineral, the material has a porosity of about 85% to about 98%, and the collagen and the acidic calcium phosphate mineral are dehydrothermally crosslinked;
about 1 part by weight to about 20 parts by weight of collagen other than that crosslinked with the acidic calcium phosphate mineral material in the collagen:acidic calcium phosphate mineral material; and
about 2 parts by weight to about 15 parts by weight of a highly acidic calcium phosphate mineral other than that crosslinked with collagen in the collagen:acidic calcium phosphate mineral material.
38. The composition of claim 37, wherein the acidic calcium phosphate mineral has a Ca:PO4 ratio from about 0.5 to about 1, and the highly acidic calcium phosphate mineral has a Ca:PO4 ratio from about 0.25 to about 0.5.
39. The composition of claim 38, wherein the acidic calcium phosphate mineral comprises one or more of calcium hydrogen phosphate dihydrate (CaHPO4.2H2O), monocalcium phosphate (Ca(H2PO4)2), calcium pyrophosphate (2CaO.P2O5), tricalcium phosphate (3CaO.P2O5), hydroxyapatite (3.33CaO.P2O5(OH)2), tetracalcium phosphate (4CaO.P2O5), or calcium carbonate (CaCO3).
40. The composition of claim 37, wherein the highly acidic calcium phosphate mineral comprises monocalcium phosphate.
41. The composition of claim 37, wherein the average particle size is about 125 microns to about 300 microns.
42. The composition of claim 37, wherein the material comprises about 60 wt % to about 75 wt % of the acidic calcium phosphate mineral.
43. The composition of claim 37, wherein the material has a porosity of about 94% to about 98%.
44. The composition of claim 37, comprising about 85 parts by volume to about 95 parts by volume of the collagen:acidic calcium phosphate mineral material and about 5 parts by volume to about 15 parts by volume collagen.
45. The composition of claim 37, further comprising about 2 parts by weight to about 150 parts by weight of a fluid.
46. The composition of claim 45, wherein the fluid is bone marrow aspirate, whole blood, serum, saline, water, or two or more thereof.
47. The composition of claim 37, further comprising one or more bone growth proteins.
48. The composition of claim 47, wherein the one or more bone growth proteins are selected from TGFβ1, TGFβ2, TGFβ3, bone morphogenic protein (BMP)-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, cartilage-derived morphogenic protein (CDMP)-1, CDMP-2, or CDMP-3.
49. A bone growth composition, comprising:
at least one bone growth protein; and
an acidic substrate comprising a substrate and at least one calcium phosphate salt;
wherein the at least one calcium phosphate salt is more than 95 wt % insoluble when 200 mg of the calcium phosphate are introduced at room temperature to 1 cc of an aqueous solution at pH 7 prior to addition of the calcium phosphate and the calcium phosphate does not excessively bind to the at least one bone growth protein.
50. A bone growth composition, comprising:
at least one bone growth protein; and
an acidic substrate comprising a substrate and at least one calcium phosphate salt, wherein each calcium phosphate salt has a pKa from about 4 to about 6.5.
US11383309 2000-12-22 2006-05-15 Composition and Process for Bone Growth and Repair Abandoned US20060246150A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09746921 US20020114795A1 (en) 2000-12-22 2000-12-22 Composition and process for bone growth and repair
US11383309 US20060246150A1 (en) 2000-12-22 2006-05-15 Composition and Process for Bone Growth and Repair

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11383309 US20060246150A1 (en) 2000-12-22 2006-05-15 Composition and Process for Bone Growth and Repair
US12849414 US8690874B2 (en) 2000-12-22 2010-08-03 Composition and process for bone growth and repair

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09746921 Continuation-In-Part US20020114795A1 (en) 2000-12-22 2000-12-22 Composition and process for bone growth and repair

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12849414 Continuation US8690874B2 (en) 2000-12-22 2010-08-03 Composition and process for bone growth and repair

Publications (1)

Publication Number Publication Date
US20060246150A1 true true US20060246150A1 (en) 2006-11-02

Family

ID=25002919

Family Applications (3)

Application Number Title Priority Date Filing Date
US09746921 Abandoned US20020114795A1 (en) 2000-12-22 2000-12-22 Composition and process for bone growth and repair
US11383309 Abandoned US20060246150A1 (en) 2000-12-22 2006-05-15 Composition and Process for Bone Growth and Repair
US12849414 Active 2021-01-11 US8690874B2 (en) 2000-12-22 2010-08-03 Composition and process for bone growth and repair

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09746921 Abandoned US20020114795A1 (en) 2000-12-22 2000-12-22 Composition and process for bone growth and repair

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12849414 Active 2021-01-11 US8690874B2 (en) 2000-12-22 2010-08-03 Composition and process for bone growth and repair

Country Status (5)

Country Link
US (3) US20020114795A1 (en)
JP (1) JP2004520106A (en)
CA (1) CA2446840A1 (en)
EP (1) EP1365792A2 (en)
WO (1) WO2002051449A3 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040081704A1 (en) * 1998-02-13 2004-04-29 Centerpulse Biologics Inc. Implantable putty material
US20080152687A1 (en) * 2006-12-21 2008-06-26 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
US20080221511A1 (en) * 2007-03-08 2008-09-11 Warsaw Orthopedic, Inc. Bone void filler
US20090112317A1 (en) * 2007-10-25 2009-04-30 Collagen Matrix, Inc. Calcium-Containing Bone Implants
US20090246244A1 (en) * 2008-03-27 2009-10-01 Warsaw Orthopedic, Inc. Malleable multi-component implants and materials therefor
US8163032B2 (en) 2002-06-13 2012-04-24 Kensey Nash Bvf Technology, Llc Devices and methods for treating defects in the tissue of a living being
WO2012068135A1 (en) 2010-11-15 2012-05-24 Zimmer Orthobiologics, Inc. Bone void fillers
US8551525B2 (en) 2010-12-23 2013-10-08 Biostructures, Llc Bone graft materials and methods
US8690874B2 (en) 2000-12-22 2014-04-08 Zimmer Orthobiologics, Inc. Composition and process for bone growth and repair
US20150110890A1 (en) * 2013-10-18 2015-04-23 Fortus Medical, Inc. Bone marrow aspirate enhanced bone graft

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949251B2 (en) * 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
US7003131B2 (en) 2002-07-09 2006-02-21 Kaleidescape, Inc. Watermarking and fingerprinting digital content using alternative blocks to embed information
US20040053197A1 (en) * 2002-09-16 2004-03-18 Zoran Minevski Biocompatible implants
GB0222291D0 (en) * 2002-09-26 2002-10-30 Smith & Nephew Adhesive bone cement
US8110222B2 (en) 2002-11-15 2012-02-07 Ut-Battelle, Llc. Composite material
DE102006006904A1 (en) 2006-02-09 2007-08-23 Ernst-Moritz-Arndt Universität Greifswald New means of hemostasis and adhesives for medical applications
JP2010538691A (en) * 2007-09-10 2010-12-16 エスビーエフ シンセティック ボーン ファクトリー ゲーエムベーハー Compositions and devices for treating bone and / or cartilage
US8114428B2 (en) 2007-03-08 2012-02-14 Sbf Synthetic Bone Factory Gmbh Methods for manufacturing a composition for treating bone and/or cartilage defects
US20090074837A1 (en) * 2007-09-19 2009-03-19 Ut-Battelle, Llc Bioresorbable Calcium-Deficient Hydroxyapatite Hydrogel Composite
WO2011143226A1 (en) 2010-05-11 2011-11-17 Howmedica Osteonics Corp. Organophosphorous, multivalent metal compounds, & polymer adhesive interpenetrating network compositions & methods
WO2012158527A3 (en) 2011-05-13 2013-01-10 Howmedica Osteonics Organophosphorous & multivalent metal compound compositions & methods
EP2529764A1 (en) 2011-05-31 2012-12-05 Curasan AG Biodegradable composite material
EP2802363A1 (en) 2012-01-09 2014-11-19 Zimmer, Inc. Composite device that combines porous metal and bone stimuli
US9220518B2 (en) 2012-05-08 2015-12-29 Zimmer, Inc. Porous spacers, instruments, and methods for foot and ankle fusion
US9649177B2 (en) * 2012-09-17 2017-05-16 Martin DEBOLD Dental implant set
WO2017127227A1 (en) * 2016-01-22 2017-07-27 Aperion Biologics Inc. Xenograft biomaterial

Citations (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180605B2 (en) *
US3968567A (en) * 1975-04-21 1976-07-13 Nevins Alan J Endodontic composition and method
US4146936A (en) * 1975-12-30 1979-04-03 Sumitomo Chemical Company Limited Implants for bones, joints and tooth roots
US4192021A (en) * 1976-05-12 1980-03-11 Batelle-Institut e.V. Bone replacement or prosthesis anchoring material
US4202055A (en) * 1976-05-12 1980-05-13 Battelle-Institut E.V. Anchorage for highly stressed endoprostheses
US4394370A (en) * 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4429691A (en) * 1979-10-08 1984-02-07 Mitsubishi Mining And Cement Company, Ltd. Method for filling in defects or hollow portions of bones
US4455256A (en) * 1981-05-05 1984-06-19 The Regents Of The University Of California Bone morphogenetic protein
US4596574A (en) * 1984-05-14 1986-06-24 The Regents Of The University Of California Biodegradable porous ceramic delivery system for bone morphogenetic protein
US4609551A (en) * 1984-03-20 1986-09-02 Arnold Caplan Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites
US4642120A (en) * 1983-03-23 1987-02-10 Ramot University Authority For Applied Research And Industrial Development Ltd. Repair of cartilage and bones
US4668295A (en) * 1985-04-25 1987-05-26 University Of Dayton Surgical cements
US4761471A (en) * 1980-08-04 1988-08-02 The Regents Of The University Of California Bone morphogenetic protein composition
US4774227A (en) * 1986-02-14 1988-09-27 Collagen Corporation Collagen compositions for bone repair containing autogeneic marrow
US4774228A (en) * 1984-07-16 1988-09-27 Collagen Corporation Polypeptide cartilage-inducing factors found in bone used in tissue proliferation
US4795467A (en) * 1985-03-28 1989-01-03 Collagen Corporation Xenogeneic collagen/mineral preparations in bone repair
US4795804A (en) * 1983-08-16 1989-01-03 The Regents Of The University Of California Bone morphogenetic agents
US4804744A (en) * 1984-01-04 1989-02-14 International Genetic Engineering, Inc. Osteogenic factors
US4843063A (en) * 1984-07-16 1989-06-27 Collagen Corporation Polypeptide cartilage-inducing factors found in bone
US4843112A (en) * 1987-03-12 1989-06-27 The Beth Israel Hospital Association Bioerodable implant composition
US4863856A (en) * 1985-04-04 1989-09-05 Verax Corporation Weighted collagen microsponge for immobilizing bioactive materials
US4863732A (en) * 1987-12-16 1989-09-05 Collagen Corporation Injectable composition for inductive bone repair
US4919670A (en) * 1988-02-03 1990-04-24 Intermedics Orthopedics, Inc. Modular humeral prosthesis
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
US4997446A (en) * 1989-09-14 1991-03-05 Intermedics Orthopedics, Inc. Method and apparatus for osseous contour reconstruction
US5001169A (en) * 1984-10-24 1991-03-19 Collagen Corporation Inductive collagen-based bone repair preparations
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5024841A (en) * 1988-06-30 1991-06-18 Collagen Corporation Collagen wound healing matrices and process for their production
US5028695A (en) * 1988-03-11 1991-07-02 Chemokol Gesellschaft Zur Entwicklung Von Kollagenprodukten Process for the manufacture of collagen membranes used for hemostasis, the dressing of wounds and for implants
US5035715A (en) * 1986-11-06 1991-07-30 Collagen Corporation Gamma irradiation of collagen/mineral mixtures
US5047031A (en) * 1988-04-20 1991-09-10 Norian Corporation In situ calcium phosphate minerals method
US5085861A (en) * 1987-03-12 1992-02-04 The Beth Israel Hospital Association Bioerodable implant composition comprising crosslinked biodegradable polyesters
US5106748A (en) * 1986-07-01 1992-04-21 Genetics Institute, Inc. Dna sequences encoding 5 proteins
US5108753A (en) * 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
US5108436A (en) * 1988-09-29 1992-04-28 Collagen Corporation Implant fixation
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5123923A (en) * 1986-07-16 1992-06-23 La Cellulose Du Pin & Universite De Bordeaux Ii Biocompatible, hydrophilic material method of manufacture and uses of same
US5137534A (en) * 1988-01-11 1992-08-11 Asahi Kogaku Kogyo K.K. Method for producing dental and medical bone prosthesis and bone prosthesis produced thereby
US5204382A (en) * 1992-02-28 1993-04-20 Collagen Corporation Injectable ceramic compositions and methods for their preparation and use
US5208219A (en) * 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
US5231169A (en) * 1990-10-17 1993-07-27 Norian Corporation Mineralized collagen
US5236704A (en) * 1988-01-28 1993-08-17 Sumitomo Pharmaceuticals Co., Ltd. Controlled release formulation
US5236456A (en) * 1989-11-09 1993-08-17 Osteotech, Inc. Osteogenic composition and implant containing same
US5290763A (en) * 1991-04-22 1994-03-01 Intermedics Orthopedics/Denver, Inc. Osteoinductive protein mixtures and purification processes
US5306303A (en) * 1991-11-19 1994-04-26 The Medical College Of Wisconsin, Inc. Bone induction method
US5393739A (en) * 1990-11-30 1995-02-28 Celtrix Pharmaceuticals, Inc. Use of bone morphogenetic protein in synergistic combination with TGF-β for bone repair
US5417975A (en) * 1988-06-02 1995-05-23 Osteomedical Limited Chemical Compound
US5426769A (en) * 1993-08-26 1995-06-20 Metalink Corp. System and method for producing input/output expansion for single chip microcomputers
US5425770A (en) * 1985-03-28 1995-06-20 Collagen Corporation Calcium phosphate/atelopeptide collagen compositions for bone repair
US5433751A (en) * 1992-04-03 1995-07-18 Inoteb Bone prosthesis material containing calcium carbonate particles dispersed in a bioresorbable polymer matrix
US5443531A (en) * 1991-04-29 1995-08-22 South African Medical Research Council Delivery system for biologically active growth or morphogenetic factors and to a method for preparing such a delivery system
US5496552A (en) * 1988-04-08 1996-03-05 Stryker Corporation Osteogenic devices
US5532217A (en) * 1992-04-24 1996-07-02 Silver; Frederick H. Process for the mineralization of collagen fibers, product produced thereby and use thereof to repair bone
US5531791A (en) * 1993-07-23 1996-07-02 Bioscience Consultants Composition for repair of defects in osseous tissues, method of making, and prosthesis
US5547378A (en) * 1994-10-21 1996-08-20 Linkow; Leonard I. Apparatus and method for closing a sinus opening during a dental implant operation
US5552454A (en) * 1988-08-09 1996-09-03 Henkel Kommanditgesellschaft Auf Aktien New materials for bone replacement and for joining bones or prostheses
US5599552A (en) * 1989-07-24 1997-02-04 Atrix Laboratories, Inc. Biodegradable polymer composition
US5639402A (en) * 1994-08-08 1997-06-17 Barlow; Joel W. Method for fabricating artificial bone implant green parts
US5707962A (en) * 1994-09-28 1998-01-13 Gensci Regeneration Sciences Inc. Compositions with enhanced osteogenic potential, method for making the same and therapeutic uses thereof
US5769897A (en) * 1991-12-13 1998-06-23 Haerle; Anton Synthetic bone
US5776193A (en) * 1995-10-16 1998-07-07 Orquest, Inc. Bone grafting matrix
US5811094A (en) * 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
US5814604A (en) * 1988-04-08 1998-09-29 Stryker Corporation Methods for inducing endochondral bone formation comprising administering CBMP-2A, CBMP-2B, and/or virants thereof
US5904717A (en) * 1986-01-28 1999-05-18 Thm Biomedical, Inc. Method and device for reconstruction of articular cartilage
US5904718A (en) * 1986-03-27 1999-05-18 Biocoll Laboratories, Inc. Delayed drug delivery system
US5910492A (en) * 1995-06-05 1999-06-08 Takeda Chemical Industries, Ltd. Osteogenic promoting pharmaceutical composition
US5916553A (en) * 1992-09-17 1999-06-29 Schmidt; Karlheinz Complex for inducing bone growth in the mastoid cavity
US5932207A (en) * 1989-11-03 1999-08-03 Schmidt; Karlheinz Complex active ingredient for the production of biological parts, especially organs for living organisms: method for the production of the same and its use
US5935594A (en) * 1993-10-28 1999-08-10 Thm Biomedical, Inc. Process and device for treating and healing a tissue deficiency
US6018095A (en) * 1996-06-14 2000-01-25 Bioland Method for preparing an implantable composite material, resulting material, implant including said material, and kit therefor
US6033438A (en) * 1997-06-03 2000-03-07 Sdgi Holdings, Inc. Open intervertebral spacer
US6071982A (en) * 1997-04-18 2000-06-06 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
US6180606B1 (en) * 1994-09-28 2001-01-30 Gensci Orthobiologics, Inc. Compositions with enhanced osteogenic potential, methods for making the same and uses thereof
US6187329B1 (en) * 1997-12-23 2001-02-13 Board Of Regents Of The University Of Texas System Variable permeability bone implants, methods for their preparation and use
US6214049B1 (en) * 1999-01-14 2001-04-10 Comfort Biomedical, Inc. Method and apparatus for augmentating osteointegration of prosthetic implant devices
US6214368B1 (en) * 1995-05-19 2001-04-10 Etex Corporation Bone substitution material and a method of its manufacture
US6261565B1 (en) * 1996-03-13 2001-07-17 Archer Daniels Midland Company Method of preparing and using isoflavones
US6264701B1 (en) * 1994-05-13 2001-07-24 Kensey Nash Corporation Device and methods for in vivo culturing of diverse tissue cells
US6277151B1 (en) * 1995-05-19 2001-08-21 Etex Corporation Cartilage growth from cell seeded ceramic compositions
US6280191B1 (en) * 1999-09-03 2001-08-28 Christopher B. Gordon Distractor suitable for permanent implantation into bone
US6335007B1 (en) * 1997-05-28 2002-01-01 Yasuhiko Shimizu Collagen gel
US6346123B1 (en) * 1996-10-24 2002-02-12 Sdgi Holdings, Inc. Ceramic fusion implants and compositions
US6376211B1 (en) * 1999-07-12 2002-04-23 Xoma Technology Ltd. Agents and methods for inhibiting F1/F0 ATPase
US6384196B1 (en) * 1998-03-24 2002-05-07 Merck Patent Gesellschaft Process for the preparation of mineralized collagen fibrils and their uses as bone substitute material
US6384197B1 (en) * 1998-03-24 2002-05-07 Merck Patent Gesellschaft Process for the preparation of mineralized collagen fibrils and their use as bone substitute material
US20020076429A1 (en) * 1998-01-28 2002-06-20 John F. Wironen Bone paste subjected to irradiative and thermal treatment
US20020082220A1 (en) * 2000-06-29 2002-06-27 Hoemann Caroline D. Composition and method for the repair and regeneration of cartilage and other tissues
US20020114795A1 (en) * 2000-12-22 2002-08-22 Thorne Kevin J. Composition and process for bone growth and repair
US6514514B1 (en) * 1997-08-14 2003-02-04 Sùlzer Biologics Inc. Device and method for regeneration and repair of cartilage lesions
US20040002558A1 (en) * 1999-02-04 2004-01-01 Mckay William F. Osteogenic paste compositions and uses thereof
US6679918B1 (en) * 1997-02-13 2004-01-20 Centerpulse Biologics Inc. Implantable putty material
US20040062816A1 (en) * 2002-07-31 2004-04-01 Atkinson Brent L. Bone repair putty
US6911212B2 (en) * 1998-02-27 2005-06-28 Musculoskeletal Transplant Foundation Malleable putty and flowable paste with allograft bone having residual calcium for filling bone defects

Family Cites Families (471)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2471598A (en) 1945-12-03 1949-05-31 Goodrich Co B F Tool for installing hollow rivets
US3368911A (en) * 1965-03-25 1968-02-13 Ethicon Inc Collagen-carbonic acid surgical sponge
US3393080A (en) 1965-10-20 1968-07-16 Fmc Corp Microcrystalline colloidal collagen dispersions in dispersing media containing dimethyl sulfoxide and water-miscible organic solvents
US3471598A (en) 1966-02-14 1969-10-07 Fmc Corp Method of producing absorbent mats
US3443261A (en) 1967-09-01 1969-05-13 Fmc Corp Prosthetic structures from microcrystalline collagen
US3767437A (en) 1971-10-20 1973-10-23 Avicon Inc Phosthetic structures derived from collagen
US3919723A (en) * 1974-05-20 1975-11-18 Friedrichsfeld Gmbh Bone shaft or bone joint prosthesis and process
US3949073A (en) 1974-11-18 1976-04-06 The Board Of Trustees Of Leland Stanford Junior University Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution
DE2501683C3 (en) 1975-01-17 1979-11-29 Ernst Leitz Wetzlar Gmbh, 6300 Wetzlar
US4233360A (en) 1975-10-22 1980-11-11 Collagen Corporation Non-antigenic collagen and articles of manufacture
US4066083A (en) * 1976-06-03 1978-01-03 Pentapharm A.G. Sterile surgical collagen product
DE2657370C2 (en) 1976-12-17 1982-11-11 Hans Dr.Med. Dr.Med.Dent. 8000 Muenchen De Scheicher
US4237559A (en) * 1979-05-11 1980-12-09 General Electric Company Bone implant embodying a composite high and low density fired ceramic construction
FR2460657B1 (en) * 1979-07-12 1984-01-20 Anvar
US4440680A (en) 1980-09-24 1984-04-03 Seton Company Macromolecular biologically active collagen articles
US4412947A (en) * 1979-09-12 1983-11-01 Seton Company Collagen sponge
JPS6052129B2 (en) 1979-10-04 1985-11-18 Kureha Chemical Ind Co Ltd
WO1981000963A1 (en) 1979-10-08 1981-04-16 Pentapharm Ag Process for preparing a collagen product for medical and cosmetic use
DE2967060D1 (en) 1979-12-18 1984-07-19 Oscobal Ag Bone replacement material and process for producing a bone replacement material
US4789732A (en) * 1980-08-04 1988-12-06 Regents Of The University Of California Bone morphogenetic protein composition
US4294753A (en) 1980-08-04 1981-10-13 The Regents Of The University Of California Bone morphogenetic protein process
US4619989A (en) 1981-05-05 1986-10-28 The Regents Of The University Of Cal. Bone morphogenetic protein composition
US4472840A (en) 1981-09-21 1984-09-25 Jefferies Steven R Method of inducing osseous formation by implanting bone graft material
FR2517315B1 (en) * 1981-11-30 1985-12-20 Tech Cuir Centre Process for the preparation of new forms of collagen, native or decrosslinked, a helical structure preserved, has associated mucopolysaccharides and their applications especially in Facial care, pharmaceutical, analytical and other
US4430760A (en) * 1981-12-18 1984-02-14 Collagen Corporation Nonstress-bearing implantable bone prosthesis
US4440750A (en) 1982-02-12 1984-04-03 Collagen Corporation Osteogenic composition and method
US4485097A (en) 1982-05-26 1984-11-27 Massachusetts Institute Of Technology Bone-equivalent and method for preparation thereof
JPS6222632B2 (en) 1983-07-15 1987-05-19 Tdk Electronics Co Ltd
US4619655A (en) * 1984-01-26 1986-10-28 University Of North Carolina Plaster of Paris as a bioresorbable scaffold in implants for bone repair
US4563489A (en) * 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
CA1295796C (en) 1984-03-27 1992-02-18 Conrad Whyne Biodegradable matrix and methods for producing same
JPH0575425B2 (en) 1984-05-28 1993-10-20 Kyocera Corp
EP0164483B1 (en) 1984-06-12 1989-08-16 Oscobal Ag Method of producing a bone replacement material
US4606910A (en) * 1984-06-28 1986-08-19 Interface Biomedical Laboratories Composite hemostatic article including a hemostatic agent onlay and methods for preparing the same
US4620327A (en) * 1984-07-05 1986-11-04 Caplan Arnold I Process of adapting soluble bone protein for use in stimulating osteoinduction
CA1259914A (en) 1984-07-06 1989-09-26 Donald G. Wallace Methods of bone repair using collagen
US4789663A (en) * 1984-07-06 1988-12-06 Collagen Corporation Methods of bone repair using collagen
USRE35694E (en) 1984-07-16 1997-12-16 Celtrix Pharmaceuticals, Inc. Polypeptide cartilage-inducing factors found in bone
US4557764A (en) 1984-09-05 1985-12-10 Collagen Corporation Process for preparing malleable collagen and the product thereof
US4629464A (en) 1984-09-25 1986-12-16 Tdk Corporation Porous hydroxyapatite material for artificial bone substitute
US4637931A (en) * 1984-10-09 1987-01-20 The United States Of America As Represented By The Secretary Of The Army Polyactic-polyglycolic acid copolymer combined with decalcified freeze-dried bone for use as a bone repair material
US4888366A (en) * 1984-10-24 1989-12-19 Collagen Corporation Inductive collagen-based bone repair preparations
US4563350A (en) * 1984-10-24 1986-01-07 Collagen Corporation Inductive collagen based bone repair preparations
US5522894A (en) 1984-12-14 1996-06-04 Draenert; Klaus Bone replacement material made of absorbable beads
US4600533A (en) 1984-12-24 1986-07-15 Collagen Corporation Collagen membranes for medical use
US4656130A (en) 1985-03-14 1987-04-07 Yissum Research Development Company Collagen coated cell growth plates
EP0198213B1 (en) * 1985-03-15 1990-08-08 Yeda Research And Development Company, Ltd. Method and compositions comprising a vitamin d derivative for the local treatment of bone fractures
US5273964A (en) 1985-03-20 1993-12-28 Lemons J E Inorganic and organic composition for treatment of bone lesions
US4992226A (en) * 1985-03-28 1991-02-12 Collagen Corporation Method of making molds with xenogeneic collagen/mineral preparations for bone repair
JPH0662679B2 (en) * 1985-06-21 1994-08-17 新田ゼラチン株式会社 Organization affinity Korah - Gen and its manufacturing method
US4693986A (en) 1985-06-25 1987-09-15 Orthomatrix, Inc. Ceramic process and products
FR2585576B1 (en) 1985-07-30 1992-01-03 Bioetica Sa substitute bone matrix osteogenesis promoting
US4776890A (en) * 1985-12-18 1988-10-11 Collagen Corporation Preparation of collagen hydroxyapatite matrix for bone repair
US4698326A (en) * 1985-12-20 1987-10-06 Regents Of The University Of Minnesota Composition and method for osseous repair
US4780450A (en) 1985-12-20 1988-10-25 The University Of Maryland At Baltimore Physically stable composition and method of use thereof for osseous repair
US5133755A (en) 1986-01-28 1992-07-28 Thm Biomedical, Inc. Method and apparatus for diodegradable, osteogenic, bone graft substitute device
GB2215209B (en) 1988-03-14 1992-08-26 Osmed Inc Method and apparatus for biodegradable, osteogenic, bone graft substitute device
US6005161A (en) 1986-01-28 1999-12-21 Thm Biomedical, Inc. Method and device for reconstruction of articular cartilage
US6311690B1 (en) 1986-03-27 2001-11-06 Gensci Orthobiologics, Inc. Bone repair material and delayed drug delivery system
JPH06100410B2 (en) 1986-04-09 1994-12-12 松下冷機株式会社 Refrigerator of the operation control device
CA1294876C (en) 1986-04-22 1992-01-28 Karl A. Piez Marrow/collagen/mineral matrix for bone defect repair
US4839215A (en) 1986-06-09 1989-06-13 Ceramed Corporation Biocompatible particles and cloth-like article made therefrom
US6432919B1 (en) 1986-07-01 2002-08-13 Genetics Institute, Inc. Bone morphogenetic protein-3 and compositions
US5543394A (en) 1986-07-01 1996-08-06 Genetics Institute, Inc. Bone morphogenetic protein 5(BMP-5) compositions
JPS6366106A (en) 1986-09-08 1988-03-24 Advance Co Ltd Bone inducing organism material
US4743229A (en) 1986-09-29 1988-05-10 Collagen Corporation Collagen/mineral mixing device and method
DE3775363D1 (en) 1986-10-22 1992-01-30 Biotechnolog Forschung Gmbh Growth-stimulating material, manufacturing method and therapeutic composition.
FI80605C (en) * 1986-11-03 1990-07-10 Biocon Oy Benkirurgisk biokompositmaterial.
US20020128722A1 (en) 1987-07-30 2002-09-12 Steven R. Jefferies Bone repair material and delayed drug delivery system
JPH062153B2 (en) 1987-09-18 1994-01-12 三菱マテリアル株式会社 Bone defects and bone void portion filler
JPH0787855B2 (en) 1987-11-06 1995-09-27 宇部興産株式会社 Human hard tissue replacement composition
CA1339083C (en) 1987-11-13 1997-07-29 Steven R. Jefferies Bone repair material and delayed drug delivery system
US4969912A (en) 1988-02-18 1990-11-13 Kelman Charles D Human collagen processing and autoimplant use
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5354557A (en) * 1988-04-08 1994-10-11 Stryker Corporation Osteogenic devices
US5344654A (en) * 1988-04-08 1994-09-06 Stryker Corporation Prosthetic devices having enhanced osteogenic properties
US4880610A (en) * 1988-04-20 1989-11-14 Norian Corporation In situ calcium phosphate minerals--method and composition
US5053212A (en) * 1988-04-20 1991-10-01 Norian Corporation Intimate mixture of calcium and phosphate sources as precursor to hydroxyapatite
US5962028A (en) 1988-04-20 1999-10-05 Norian Corporation Carbonated hydroxyapatite compositions and uses
EP0349048A3 (en) 1988-06-27 1990-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Osteogenic growth factors derived from regenerating bone marrow
US5110604A (en) 1988-06-30 1992-05-05 Collagen Corporation Processes for producing collagen matrixes and methods of using same
JPH0773602B2 (en) 1988-07-23 1995-08-09 新田ゼラチン株式会社 Medical and for dental curable material
US4948540A (en) 1988-08-01 1990-08-14 Semex Medical, Inc. Method of preparing collagen dressing sheet material
US4975526A (en) 1989-02-23 1990-12-04 Creative Biomolecules, Inc. Bone collagen matrix for zenogenic implants
US5162114A (en) * 1989-02-23 1992-11-10 Stryker Corporation Bone collagen matrix for xenogenic implants
US5573771A (en) 1988-08-19 1996-11-12 Osteomedical Limited Medicinal bone mineral products
US5207710A (en) * 1988-09-29 1993-05-04 Collagen Corporation Method for improving implant fixation
US5258029A (en) * 1988-09-29 1993-11-02 Collagen Corporation Method for improving implant fixation
US5475052A (en) 1988-11-21 1995-12-12 Collagen Corporation Collagen-synthetic polymer matrices prepared using a multiple step reaction
US5306500A (en) 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
GB8827986D0 (en) 1988-11-30 1989-01-05 Geistlich Soehne Ag Chemical product
US4891359A (en) * 1988-12-08 1990-01-02 Johnson & Johnson Patient Care, Inc. Hemostatic collagen paste composition
US5034059A (en) * 1989-02-17 1991-07-23 Norian Corporation Composition comprising octacalcium phosphate crystals and polypeptide
US5061286A (en) * 1989-08-18 1991-10-29 Osteotech, Inc. Osteoprosthetic implant
US5422340A (en) 1989-09-01 1995-06-06 Ammann; Arthur J. TGF-βformulation for inducing bone growth
US5158934A (en) * 1989-09-01 1992-10-27 Genentech, Inc. Method of inducing bone growth using TGF-β
US5073373A (en) * 1989-09-21 1991-12-17 Osteotech, Inc. Flowable demineralized bone powder composition and its use in bone repair
US5290558A (en) 1989-09-21 1994-03-01 Osteotech, Inc. Flowable demineralized bone powder composition and its use in bone repair
EP0439689B1 (en) * 1990-01-04 1994-12-21 L.B. BOHLE PHARMATECHNIK GmbH Mixgranulator
US5071655A (en) 1990-01-12 1991-12-10 Baylink David J Pharmaceutical combination for treatment of bone-wasting diseases
US5492697A (en) * 1990-03-05 1996-02-20 Board Of Regents, Univ. Of Texas System Biodegradable implant for fracture nonunions
US5290494A (en) 1990-03-05 1994-03-01 Board Of Regents, The University Of Texas System Process of making a resorbable implantation device
US5164187A (en) * 1990-04-05 1992-11-17 Norian Corporation Hydroxyapatite prosthesis coatings
JP2978203B2 (en) * 1990-04-20 1999-11-15 日本特殊陶業株式会社 Method of manufacturing a ceramic body having a bioactive surface layer
US5645591A (en) 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix
US5364839A (en) 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
GB9014052D0 (en) 1990-06-25 1990-08-15 Farmos Oy Bioceramic system for delivery of a bioactive compound
US5274078A (en) * 1990-08-08 1993-12-28 Showa Denko K.K. Process for producing collagen powder
US5263985A (en) * 1990-08-14 1993-11-23 Pfizer Hospital Products Group, Inc. Bone growth stimulator
DE69120177T2 (en) 1990-09-10 1996-10-10 Synthes Ag Membrane for bone regeneration
JP2621622B2 (en) * 1990-09-27 1997-06-18 三菱マテリアル株式会社 Hydraulic calcium phosphate cement
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5169837A (en) * 1991-03-28 1992-12-08 Allelix Biopharmaceuticals Inc. Isolated osteogenic factor
JP2774695B2 (en) 1991-03-29 1998-07-09 コラーゲン コーポレイション Apparatus and method for treatment of facial wrinkles
US5262166A (en) * 1991-04-17 1993-11-16 Lty Medical Inc Resorbable bioactive phosphate containing cements
US5563124A (en) * 1991-04-22 1996-10-08 Intermedics Orthopedics/ Denver, Inc. Osteogenic product and process
EP0511868B1 (en) 1991-05-01 1996-09-25 Chichibu Onoda Cement Corporation Medical or dental hardening compositions
DE4120325A1 (en) * 1991-06-20 1992-12-24 Merck Patent Gmbh Implant material
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
DE69228118D1 (en) 1991-06-25 1999-02-18 Genetics Inst BMP 9 compositions
DE4121043A1 (en) 1991-06-26 1993-01-07 Merck Patent Gmbh Bone substitute material with fgf
CA2071137A1 (en) 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
US5356629A (en) 1991-07-12 1994-10-18 United States Surgical Corporation Composition for effecting bone repair
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
US5171579A (en) 1991-10-11 1992-12-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
GB9122329D0 (en) 1991-10-22 1991-12-04 Isis Innovation Bioactive material
WO1993012736A1 (en) 1991-12-30 1993-07-08 Norian Corporation Mineralized collagen
WO1993013815A1 (en) 1992-01-13 1993-07-22 Lucocer Aktiebolag An implant
US5314476A (en) 1992-02-04 1994-05-24 Osteotech, Inc. Demineralized bone particles and flowable osteogenic composition containing same
US6537574B1 (en) 1992-02-11 2003-03-25 Bioform, Inc. Soft tissue augmentation material
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
EP0626868A1 (en) 1992-02-19 1994-12-07 EBERLIN, Jean-Luc Collagen- and fibrin adhesive-based graft for osteocartilaginous reconstruction, and preparation method therefor
DE69333556D1 (en) * 1992-02-28 2004-07-22 Cohesion Tech Inc Injektierbare ceramic compounds and processes for their preparation and use
US5320844A (en) * 1992-03-12 1994-06-14 Liu Sung Tsuen Composite materials for hard tissue replacement
GB9206509D0 (en) * 1992-03-25 1992-05-06 Jevco Ltd Heteromorphic sponges containing active agents
ES2166754T3 (en) 1992-04-11 2002-05-01 Karlheinz Prof Dr Dr Schmidt Procedure for obtaining complexes of active ingredient.
CA2093836A1 (en) 1992-04-24 1993-10-25 Wayne Gombotz Biodegradable tgf-.beta. delivery system for bone regeneration
EP0568334A1 (en) * 1992-05-01 1993-11-03 Amgen Inc. Collagen-containing sponges as drug delivery for proteins
US5366756A (en) * 1992-06-15 1994-11-22 United States Surgical Corporation Method for treating bioabsorbable implant material
GB9215356D0 (en) 1992-07-20 1992-09-02 Univ Reading The Bone materials
US5428022A (en) * 1992-07-29 1995-06-27 Collagen Corporation Composition of low type III content human placental collagen
JP3289393B2 (en) 1992-09-18 2002-06-04 ソニー株式会社 Charging system for video camera
DE4242889A1 (en) 1992-12-18 1994-06-23 Merck Patent Gmbh Hohlendoprothesen with bone growth-promoting filling
DE4244466C2 (en) 1992-12-24 1995-02-23 Pharmatech Gmbh A process for the production of pseudolatices and micro- or nanoparticles and their use for the production of pharmaceutical preparations
US5670483A (en) 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
DE69403439D1 (en) * 1993-01-12 1997-07-03 Genentech Inc TGF-beta composition to induce bone growth of
US5522893A (en) 1993-03-12 1996-06-04 American Dental Association Health Foundation Calcium phosphate hydroxyapatite precursor and methods for making and using the same
FR2702757B1 (en) * 1993-03-17 1995-06-16 Rhone Poulenc Chimie New aluminum phosphate, process for its preparation and its use in the preparation of materials comprising a binder and ceramic parts.
US5565502A (en) 1993-03-24 1996-10-15 Children's Medical Center Corporation Isolation of the calcium-phosphate crystals of bone
CA2119090A1 (en) 1993-03-26 1994-09-27 Wayne R. Gombotz Compositions for controlled release of biologically active tgf-.beta.
CA2121192A1 (en) 1993-04-21 1994-10-22 Kiminori Atsumi Collagen membranes
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
FR2706768B1 (en) * 1993-05-13 1995-12-01 Inoteb
FR2705235B1 (en) 1993-05-13 1995-07-13 Inoteb Use of particles of a biocompatible and bioabsorbable calcium salt as active ingredient in the preparation of a medicament for the local treatment of demineralizing bone diseases.
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
ES2265146T3 (en) 1993-08-26 2007-02-01 Genetics Institute, Llc human bone morphogenetic proteins for use in nerve regeneration.
WO1995008304A1 (en) 1993-09-21 1995-03-30 The Penn State Research Foundation Bone substitute composition comprising hydroxyapatite and a method of production therefor
US5681873A (en) 1993-10-14 1997-10-28 Atrix Laboratories, Inc. Biodegradable polymeric composition
US5507813A (en) 1993-12-09 1996-04-16 Osteotech, Inc. Shaped materials derived from elongate bone particles
DE9402499U1 (en) 1994-02-16 1994-07-14 Bohle L B Pharmatech Gmbh agitator
WO1995025550A1 (en) 1994-03-22 1995-09-28 Organogenesis Inc. Biocompatible prosthetic devices
CA2142209A1 (en) 1994-03-29 1995-09-30 George H. Chu Collagen implants having improved tensile properties
GB9407135D0 (en) 1994-04-11 1994-06-01 Aberdeen University And Plasma Treatment of osteoporosis
US20020032488A1 (en) 1994-05-13 2002-03-14 Brekke John H. Device for regeneration of articular cartilage and other tissue
US7963997B2 (en) 2002-07-19 2011-06-21 Kensey Nash Corporation Device for regeneration of articular cartilage and other tissue
DE69527957D1 (en) 1994-05-24 2002-10-02 Implico Bv Biomaterial and implant for repair and replacement of bone
US5906827A (en) 1994-06-03 1999-05-25 Creative Biomolecules, Inc. Matrix for the manufacture of autogenous replacement body parts
US5603955A (en) 1994-07-18 1997-02-18 University Of Cincinnati Enhanced loading of solutes into polymer gels
EP0693523B1 (en) 1994-07-19 2002-11-20 Col-Bar R 6 D Ltd. Collagen-based matrix
US5496399A (en) 1994-08-23 1996-03-05 Norian Corporation Storage stable calcium phosphate cements
US20010014667A1 (en) 1998-01-05 2001-08-16 Chen Charles C. Compositions with enhanced osteogenic potential, methods for making the same and therapeutic uses thereof
EP0784985A4 (en) 1994-09-30 2000-05-31 Yamanouchi Pharma Co Ltd Osteoplastic graft
WO1996010374A1 (en) 1994-10-03 1996-04-11 Otogen Corporation Differentially biodegradable biomedical implants
US5709934A (en) * 1994-11-22 1998-01-20 Tissue Engineering, Inc. Bipolymer foams having extracellular matrix particulates
CA2164045A1 (en) 1994-11-30 1996-05-31 Kevin Cooper Hard tissue bone cements and substitutes
US5928635A (en) 1994-12-07 1999-07-27 Schmidt; Karlheinz Process for producing active agent complexes
US5741329A (en) 1994-12-21 1998-04-21 Board Of Regents, The University Of Texas System Method of controlling the pH in the vicinity of biodegradable implants
JP3450920B2 (en) 1994-12-26 2003-09-29 京セラ株式会社 Method of manufacturing bioprosthetic member
US5549671A (en) 1994-12-28 1996-08-27 Mcghan Medical Corporation Adjunctive filler material for fluid-filled prosthesis
CA2186616A1 (en) 1995-02-02 1996-08-08 Anjun Liu Completely dissolved bone tissue and method for producing the same
US6371985B1 (en) 1995-03-09 2002-04-16 Robert S. Goldberg Prostheses restrained by immediate attachment while ingrowth proceeds naturally over time
US5674290A (en) 1995-04-05 1997-10-07 Li; Shu-Tung Water-stabilized biopolymeric implants
US5733337A (en) 1995-04-07 1998-03-31 Organogenesis, Inc. Tissue repair fabric
US5750146A (en) 1995-04-28 1998-05-12 Matrix Pharmaceutical, Inc. Translucent collagen formulations with a cytotoxic drug
US5635372A (en) 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
US6287341B1 (en) 1995-05-19 2001-09-11 Etex Corporation Orthopedic and dental ceramic implants
US6953594B2 (en) 1996-10-10 2005-10-11 Etex Corporation Method of preparing a poorly crystalline calcium phosphate and methods of its use
US7517539B1 (en) 1996-10-16 2009-04-14 Etex Corporation Method of preparing a poorly crystalline calcium phosphate and methods of its use
US6027742A (en) 1995-05-19 2000-02-22 Etex Corporation Bioresorbable ceramic composites
CN1133462C (en) * 1995-06-05 2004-01-07 遗传学研究所有限责任公司 Methods and compositions for healing and repair of connective tissue attachment
US6352972B1 (en) 1995-06-06 2002-03-05 Marcel E. Nimni Bone morphogenetic proteins and their use in bone growth
US5677284A (en) 1995-06-06 1997-10-14 Regen Biologics, Inc. Charged collagen particle-based delivery matrix
CN1192700A (en) 1995-06-06 1998-09-09 基因科学再生实验室有限公司 Modified osteogenic materials
US6039762A (en) 1995-06-07 2000-03-21 Sdgi Holdings, Inc. Reinforced bone graft substitutes
US5674292A (en) * 1995-06-07 1997-10-07 Stryker Corporation Terminally sterilized osteogenic devices and preparation thereof
CA2172917A1 (en) 1995-06-07 1996-12-08 Hugh R. Mcmullin Moldable collagen compositions for hard tissue repair and augmentation
JP3881707B2 (en) 1995-07-20 2007-02-14 学校法人松本歯科大学 Method for producing osteogenic composition using the manufacturing method and osteogenesis promoter of bone formation promoter
DE69634384D1 (en) 1995-09-01 2005-03-31 Millenium Biologix Inc calcium phosphate phases to support the bone cell activity particularly suitable stabilized composition of
US5716413A (en) 1995-10-11 1998-02-10 Osteobiologics, Inc. Moldable, hand-shapable biodegradable implant material
US6423095B1 (en) 1995-10-16 2002-07-23 Sdgi Holdings, Inc. Intervertebral spacers
US6902584B2 (en) 1995-10-16 2005-06-07 Depuy Spine, Inc. Bone grafting matrix
US6048964A (en) 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US7026292B1 (en) 1995-12-12 2006-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
DE69733292T2 (en) 1996-03-01 2006-04-27 Isotis N.V. A method for in vitro production of bone
US6299905B1 (en) 1996-04-16 2001-10-09 Depuy Orthopaedics, Inc. Bioerodable polymeric adhesives for tissue repair
US5824084A (en) 1996-07-03 1998-10-20 The Cleveland Clinic Foundation Method of preparing a composite bone graft
JPH1033657A (en) 1996-07-23 1998-02-10 Dainippon Ink & Chem Inc In vivo decomposing material and its manufacture
US5964807A (en) 1996-08-08 1999-10-12 Trustees Of The University Of Pennsylvania Compositions and methods for intervertebral disc reformation
ES2208974T3 (en) 1996-08-23 2004-06-16 Cook Biotech, Inc. Prosthetic grafts, materials and methods.
US6189537B1 (en) * 1996-09-06 2001-02-20 Lifenet Process for producing osteoinductive bone, and osteoinductive bone produced thereby
US5676146B1 (en) 1996-09-13 2000-04-18 Osteotech Inc Surgical implant containing a resorbable radiopaque marker and method of locating such within a body
US5964805A (en) 1997-02-12 1999-10-12 Stone; Kevin R. Method and paste for articular cartilage transplantation
US6165487A (en) 1996-09-30 2000-12-26 Children's Medical Center Corporation Methods and compositions for programming an organic matrix for remodeling into a target tissue
WO1998017330A1 (en) 1996-10-24 1998-04-30 Sdgi Holdings, Inc. Ceramic fusion implants and compositions containing osteoinductive factors
FI105159B (en) * 1996-10-25 2000-06-30 Biocon Ltd Surgical implant, device, or portion thereof
EP0842670A1 (en) 1996-11-13 1998-05-20 ISE International Co., Ltd. Biomedical materials
CA2304093A1 (en) 1997-09-19 1999-04-01 Reprogenesis, Inc. Improved hydrogel for tissue engineering
ES2256898T3 (en) 1996-12-20 2006-07-16 Alza Corporation Gel composition and procedures.
WO1998030252A1 (en) 1997-01-09 1998-07-16 Cohesion Technologies, Inc. Methods and apparatuses for making swellable uniformly shaped devices from polymeric materials
WO1998034655A1 (en) 1997-02-07 1998-08-13 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
EP1844798A1 (en) 1997-02-13 2007-10-17 Zimmer Orthobiologics, Inc. Implantable putty material
WO1998035653A1 (en) 1997-02-13 1998-08-20 Benedict, James, A. Implantable collagen-containing putty material
US20040081704A1 (en) 1998-02-13 2004-04-29 Centerpulse Biologics Inc. Implantable putty material
US6383810B2 (en) 1997-02-14 2002-05-07 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
US5830340A (en) 1997-03-05 1998-11-03 Trumem International Llc Method for making a composite filter
GB9704749D0 (en) 1997-03-07 1997-04-23 Univ London Tissue Implant
US20020098222A1 (en) 1997-03-13 2002-07-25 John F. Wironen Bone paste
JP3679570B2 (en) * 1997-03-14 2005-08-03 ペンタックス株式会社 Bone substitute material and a method of manufacturing the same
US7041641B2 (en) 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
EP0980272A1 (en) 1997-04-30 2000-02-23 Nobel Biocare AB Calcium-phosphate coated implant element
US5948426A (en) 1997-05-03 1999-09-07 Jefferies; Steven R. Method and article to induce hematopoietic expansion
US20030032586A1 (en) 1997-05-15 2003-02-13 David C. Rueger Compositions for morphogen-induced osteogenesis
US5972368A (en) 1997-06-11 1999-10-26 Sdgi Holdings, Inc. Bone graft composites and spacers
WO1998058602A1 (en) 1997-06-20 1998-12-30 Alfred Farrington Bone grafting material
US6123957A (en) 1997-07-16 2000-09-26 Jernberg; Gary R. Delivery of agents and method for regeneration of periodontal tissues
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
US5910315A (en) 1997-07-18 1999-06-08 Stevenson; Sharon Allograft tissue material for filling spinal fusion cages or related surgical spaces
US6471993B1 (en) 1997-08-01 2002-10-29 Massachusetts Institute Of Technology Three-dimensional polymer matrices
US6090996A (en) 1997-08-04 2000-07-18 Collagen Matrix, Inc. Implant matrix
US6241771B1 (en) 1997-08-13 2001-06-05 Cambridge Scientific, Inc. Resorbable interbody spinal fusion devices
US6511958B1 (en) * 1997-08-14 2003-01-28 Sulzer Biologics, Inc. Compositions for regeneration and repair of cartilage lesions
GB2329181B (en) 1997-09-11 2002-03-13 Johnson & Johnson Medical Bioabsorbable Wound Dressing Materials
US5997895A (en) 1997-09-16 1999-12-07 Integra Lifesciences Corporation Dural/meningeal repair product using collagen matrix
US6136029A (en) 1997-10-01 2000-10-24 Phillips-Origen Ceramic Technology, Llc Bone substitute materials
US6296667B1 (en) 1997-10-01 2001-10-02 Phillips-Origen Ceramic Technology, Llc Bone substitutes
US6425949B1 (en) 1997-10-07 2002-07-30 Dr. H. C. Robert Mathys Stiftung Hydraulic surgical cement
US7141072B2 (en) * 1998-10-05 2006-11-28 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method for promoting regeneration of surface cartilage in a damaged joint using multi-layer covering
US6417247B1 (en) 1997-10-14 2002-07-09 Beth L. Armstrong Polymer/ceramic composites
US6309420B1 (en) 1997-10-14 2001-10-30 Parallax Medical, Inc. Enhanced visibility materials for implantation in hard tissue
EP1030676B1 (en) * 1997-10-30 2005-09-14 The General Hospital Corporation Bonding of cartilaginous matrices using isolated chondrocytes
JPH11164880A (en) 1997-12-05 1999-06-22 Nippon Electric Glass Co Ltd Manufacture of titania containing inorganic/organic hybrid bioactive material
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US5899939A (en) 1998-01-21 1999-05-04 Osteotech, Inc. Bone-derived implant for load-supporting applications
US20020018796A1 (en) * 1998-01-28 2002-02-14 John F. Wironen Thermally sterilized bone paste
US6123731A (en) 1998-02-06 2000-09-26 Osteotech, Inc. Osteoimplant and method for its manufacture
US5958430A (en) 1998-02-20 1999-09-28 Battelle Memorial Institute Thin film composition with biological substance and method of making
US6326018B1 (en) 1998-02-27 2001-12-04 Musculoskeletal Transplant Foundation Flexible sheet of demineralized bone
US6030635A (en) 1998-02-27 2000-02-29 Musculoskeletal Transplant Foundation Malleable paste for filling bone defects
US7045141B2 (en) 1998-02-27 2006-05-16 Musculoskeletal Transplant Foundation Allograft bone composition having a gelatin binder
US20060204544A1 (en) 2002-05-20 2006-09-14 Musculoskeletal Transplant Foundation Allograft bone composition having a gelatin binder
US6432436B1 (en) 2000-10-03 2002-08-13 Musculoskeletal Transplant Foundation Partially demineralized cortical bone constructs
US20010016646A1 (en) 1998-03-20 2001-08-23 David C. Rueger Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects
US6395036B1 (en) 1998-04-06 2002-05-28 Isis Innovation Limited Composite material and methods of making the same
US6662805B2 (en) 1999-03-24 2003-12-16 The Johns Hopkins University Method for composite cell-based implants
JP3360810B2 (en) 1998-04-14 2003-01-07 ペンタックス株式会社 Method of manufacturing a bone substitute material
US6933326B1 (en) 1998-06-19 2005-08-23 Lifecell Coporation Particulate acellular tissue matrix
JP2000022044A (en) 1998-07-02 2000-01-21 Mitsubishi Electric Corp Semiconductor device and its manufacture
DE69935142T2 (en) 1998-07-13 2007-10-31 Gs Development Ab Material for bone reconstruction
WO2000007639A1 (en) 1998-08-07 2000-02-17 Tissue Engineering, Inc. Bone precursor compositions
US6551355B1 (en) 1998-08-14 2003-04-22 Cambridge Scientific, Inc. Tissue transplant coated with biocompatible biodegradable polymer
US6406498B1 (en) 1998-09-04 2002-06-18 Bionx Implants Oy Bioactive, bioabsorbable surgical composite material
US6168801B1 (en) * 1998-09-09 2001-01-02 Cardiac Pacemakers, Inc. Controlled release drug delivery
US6132468A (en) 1998-09-10 2000-10-17 Mansmann; Kevin A. Arthroscopic replacement of cartilage using flexible inflatable envelopes
EP0987031B1 (en) 1998-09-15 2003-04-02 IsoTis N.V. Method for coating medical implants
CA2282075A1 (en) * 1998-09-15 2000-03-15 Isotis B.V. Osteoinduction
WO2001078798A1 (en) 2000-02-10 2001-10-25 Regeneration Technologies, Inc. Assembled implant
DE19855890A1 (en) 1998-12-03 2000-06-08 Nerlich Michael Porous composite matrix, their preparation and use
FI110062B (en) 1998-12-11 2002-11-29 Antti Yli-Urpo The new composite and its use
US6454787B1 (en) 1998-12-11 2002-09-24 C. R. Bard, Inc. Collagen hemostatic foam
DE69918717D1 (en) 1998-12-14 2004-08-19 Osteotech Inc Bone graft from bone particles
US6200347B1 (en) 1999-01-05 2001-03-13 Lifenet Composite bone graft, method of making and using same
US6136030A (en) 1999-01-12 2000-10-24 Purzer Pharmaceutical Co., Ltd. Process for preparing porous bioceramic materials
US6383519B1 (en) 1999-01-26 2002-05-07 Vita Special Purpose Corporation Inorganic shaped bodies and methods for their production and use
JP2002536077A (en) 1999-02-04 2002-10-29 エスディージーアイ・ホールディングス・インコーポレーテッド Highly osteogenic sponge compositions that are mineralized and their uses
WO2000047114A1 (en) * 1999-02-12 2000-08-17 Collagenesis, Inc. Injectable collagen-based delivery system for bone morphogenic proteins
US6696073B2 (en) * 1999-02-23 2004-02-24 Osteotech, Inc. Shaped load-bearing osteoimplant and methods of making same
US6294187B1 (en) 1999-02-23 2001-09-25 Osteotech, Inc. Load-bearing osteoimplant, method for its manufacture and method of repairing bone using same
US20070233272A1 (en) 1999-02-23 2007-10-04 Boyce Todd M Shaped load-bearing osteoimplant and methods of making same
US8133421B2 (en) 1999-02-23 2012-03-13 Warsaw Orthopedic, Inc. Methods of making shaped load-bearing osteoimplant
US6322785B1 (en) 1999-03-02 2001-11-27 Natrex Technologies Methods and compositions for bone graft implants
JP2000262608A (en) * 1999-03-12 2000-09-26 Mitsubishi Materials Corp Composite type bone packing material
US6205032B1 (en) 1999-03-16 2001-03-20 Cts Corporation Low temperature co-fired ceramic with improved registration
WO2000054821A1 (en) 1999-03-16 2000-09-21 Regeneration Technologies, Inc. Molded implants for orthopedic applications
US6506217B1 (en) * 1999-03-29 2003-01-14 Arnett Facial Reconstruction Courses, Inc. Moldable post-implantation bone filler and method
JP3400740B2 (en) * 1999-04-13 2003-04-28 東芝セラミックス株式会社 Calcium phosphate porous sintered body and manufacturing method thereof
WO2000070018A3 (en) 1999-05-18 2001-08-30 Cryolife Inc Self-supporting, shaped, three-dimensional biopolymeric materials and methods
JP4472804B2 (en) 1999-05-18 2010-06-02 学校法人松本歯科大学 Bone filling agent and a method of manufacturing the same
US6921412B1 (en) 1999-05-18 2005-07-26 Cryolife, Inc. Self-supporting, shaped, three-dimensional biopolymeric materials and methods
WO2000071178A1 (en) 1999-05-19 2000-11-30 Ecole Polytechnique Federale De Lausanne (Epfl) Calcium phosphate bone substitute
JP2003500112A (en) 1999-05-20 2003-01-07 ボストン・ユニバーシティ Anatomically accurate polymer-reinforced bioactive prostheses
US6251143B1 (en) 1999-06-04 2001-06-26 Depuy Orthopaedics, Inc. Cartilage repair unit
US7371408B1 (en) 1999-06-07 2008-05-13 Wright Medical Technology, Inc. Bone graft substitute composition
EP1203074A4 (en) 1999-06-29 2003-09-10 J Alexander Marchosky Compositions and methods for forming and strengthening bone
US6479565B1 (en) 1999-08-16 2002-11-12 Harold R. Stanley Bioactive ceramic cement
US6300315B1 (en) 1999-08-28 2001-10-09 Ceramedical, Inc. Mineralized collagen membrane and method of making same
US6221109B1 (en) 1999-09-15 2001-04-24 Ed. Geistlich Söhne AG fur Chemische Industrie Method of protecting spinal area
US6429748B2 (en) 1999-09-30 2002-08-06 Nortel Networks Limited Oscillation circuits featuring coaxial resonators
US20020082594A1 (en) 1999-10-02 2002-06-27 Cary Hata Injectable biomaterial and methods for use thereof
JP4703926B2 (en) 1999-10-15 2011-06-15 ジェネティクス インスティテュート,エルエルシー The formulation of hyaluronic acid for delivering a bone morphogenetic protein
US6206924B1 (en) 1999-10-20 2001-03-27 Interpore Cross Internat Three-dimensional geometric bio-compatible porous engineered structure for use as a bone mass replacement or fusion augmentation device
DE60036015D1 (en) 1999-10-25 2007-09-27 Ghimas Spa Invasive medical device for tissue regeneration in particular controlled
EP1229858B1 (en) 1999-11-01 2007-05-23 Osteobiologics, Inc. Biodegradable polymer/ceramic implant material with bimodal degradation profile
DE19957388A1 (en) 1999-11-24 2001-06-13 Michael Sittinger Chondroinductive and Implantable substrates for cartilage healing and -protektion
WO2001039680A1 (en) 1999-11-30 2001-06-07 Bionx Implants, Oy Bioabsorbable, osteopromoting fixation plate
US20010044413A1 (en) 1999-12-01 2001-11-22 Glenn Pierce In situ bioreactors and methods of use thereof
DE60033055D1 (en) * 1999-12-06 2007-03-08 Warsaw Orthopedic Inc Intervertebral disc treatment device
WO2001041821A1 (en) 1999-12-09 2001-06-14 Biosyntech Canada Inc. Mineral-polymer hybrid composition
EP1274468A1 (en) 1999-12-28 2003-01-15 Osteotech, Inc., Calcium phosphate bone graft material and osteoimplant fabricated therefrom
US20010037091A1 (en) 1999-12-29 2001-11-01 Wironen John F. System for reconstituting pastes and methods of using same
US6379385B1 (en) 2000-01-06 2002-04-30 Tutogen Medical Gmbh Implant of bone matter
US20030152606A1 (en) 2000-01-28 2003-08-14 Thomas Gerber Inorganic resorbable bone substitute material and production method
US20010041792A1 (en) 2000-02-03 2001-11-15 Donda Russell S. Extraction of growth factors from tissue
KR20020082231A (en) 2000-03-03 2002-10-30 스미쓰 앤드 네퓨, 인크. Shaped Particle and Composition for Bone Deficiency and Method of Making the Particle
US6537589B1 (en) 2000-04-03 2003-03-25 Kyung Won Medical Co., Ltd. Calcium phosphate artificial bone as osteoconductive and biodegradable bone substitute material
US6719987B2 (en) 2000-04-17 2004-04-13 Nucryst Pharmaceuticals Corp. Antimicrobial bioabsorbable materials
CN1106861C (en) * 2000-05-19 2003-04-30 清华大学 Preparation method of nanometer phase calcium-phosphorus salt/collagen/polylactic acid bone composite material
US20020022885A1 (en) * 2000-05-19 2002-02-21 Takahiro Ochi Biomaterial
FR2809412A1 (en) 2000-05-26 2001-11-30 Coletica Use of aquatic collagen for making supports for tissue engineering, particularly skin or tissue equivalents for surgical repair, studying aging processes and screening
US6991652B2 (en) * 2000-06-13 2006-01-31 Burg Karen J L Tissue engineering composite
DE10029520A1 (en) * 2000-06-21 2002-01-17 Merck Patent Gmbh Coating for metallic implant materials
GB2365234B (en) 2000-06-21 2004-03-31 Sgs Thomson Microelectronics Selective modification of clock pulses
DK177997B1 (en) * 2000-07-19 2015-02-23 Ed Geistlich Söhne Ag Für Chemische Ind Bone Material and collage combination for repairing damaged joints
US9387094B2 (en) * 2000-07-19 2016-07-12 Warsaw Orthopedic, Inc. Osteoimplant and method of making same
WO2002007961A1 (en) 2000-07-21 2002-01-31 3Tex, Inc. Three-dimensional fiber scaffolds for injury repair
JP5154729B2 (en) 2000-08-04 2013-02-27 オルソゲム・リミテッド Porous artificial bone grafts and a method for producing
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6579532B1 (en) 2000-09-08 2003-06-17 Ferro Corporation Orthopedic mixtures prepared by supercritical fluid processing techniques
US6599516B1 (en) 2000-09-14 2003-07-29 Etex Corporation Malleable implant containing solid element that resorbs or fractures to provide access channels
WO2002024107A3 (en) 2000-09-20 2002-07-04 Islet Sheet Medical Llc Fabrication of thin sheet bio-artificial organs
US20020072804A1 (en) 2000-09-20 2002-06-13 Donda Russell S. Combination biological-non-biological material prosthetic implant and method
US7052517B2 (en) 2000-10-24 2006-05-30 Vita Special Purpose Corporation Delivery device for biological composites and method of preparation thereof
US6736799B1 (en) 2000-10-24 2004-05-18 Vita Licensing, Inc. Delivery device for biological composites and method of preparation thereof
WO2002034116A3 (en) 2000-10-24 2003-02-27 William F Mckay Spinal fusion methods and devices
EP1335771A4 (en) 2000-10-24 2006-06-07 Sdgi Holdings Inc Methods and instruments for treating pseudoarthrosis
WO2002040963A3 (en) 2000-10-24 2003-01-16 Vita Special Purpose Corp Biologically active composites and methods for their production and use
US6547866B1 (en) 2000-10-30 2003-04-15 Howmedica Osteonics Corp. Porous calcium phosphate cement
US6576249B1 (en) 2000-11-13 2003-06-10 El Gendler Bone putty and method
US20020090725A1 (en) 2000-11-17 2002-07-11 Simpson David G. Electroprocessed collagen
WO2002040073A1 (en) 2000-11-20 2002-05-23 Université De Genève Endosseous implant
US7192604B2 (en) 2000-12-22 2007-03-20 Ethicon, Inc. Implantable biodegradable devices for musculoskeletal repair or regeneration
US20020082697A1 (en) 2000-12-22 2002-06-27 Damien Christopher J. Implantable osteogenic material
US6500464B2 (en) 2000-12-28 2002-12-31 Ortec International, Inc. Bilayered collagen construct
US6485709B2 (en) 2001-01-23 2002-11-26 Addent Inc. Dental bleaching gel composition, activator system and method for activating a dental bleaching gel
DE60115192T2 (en) 2001-02-26 2006-08-10 Ethicon, Inc. Biocompatible composite foam
US6949251B2 (en) 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
EP1379287A1 (en) 2001-04-12 2004-01-14 Therics, Inc. Method and apparatus for engineered regenerative biostructures
ES2424614T3 (en) * 2001-05-01 2013-10-07 Amedica Corporation radiolucent bone graft
JP2002325831A (en) 2001-05-02 2002-11-12 Asahi Optical Co Ltd Filling material for organism and manufacture thereof
US6444222B1 (en) 2001-05-08 2002-09-03 Verigen Transplantation Services International Ag Reinforced matrices
GB0115320D0 (en) 2001-06-22 2001-08-15 Univ Nottingham Matrix
JP4294474B2 (en) * 2001-07-16 2009-07-15 デピュイ・プロダクツ・インコーポレイテッド Meniscal reproducing apparatus
JP2004535245A (en) 2001-07-16 2004-11-25 デピュイ・プロダクツ・インコーポレイテッド Porous extracellular matrix scaffold and Methods
EP1464345B1 (en) 2003-04-03 2009-12-30 Dennis W. Szymaitis Bone growth and adjacent tissue regeneration composition
US7105182B2 (en) 2001-07-25 2006-09-12 Szymaitis Dennis W Periodontal regeneration composition and method of using same
CN1265845C (en) 2001-07-30 2006-07-26 株式会社日本组织工程 Tissue regenerating base material, implanting material and method of producing the same
US7132110B2 (en) 2001-08-30 2006-11-07 Isotis Orthobiologics, Inc. Tissue repair compositions and methods for their manufacture and use
JP4330991B2 (en) 2001-10-01 2009-09-16 スキャンディウス・バイオメディカル・インコーポレーテッド Apparatus and method for repairing defects in articular cartilage
JP2005505351A (en) 2001-10-12 2005-02-24 オステオテック インコーポレーテッド Improved bone graft
CA2463850C (en) 2001-10-18 2013-03-26 Lifecell Corporation Remodeling of tissues and organs
JP4408603B2 (en) 2001-10-19 2010-02-03 新田ゼラチン株式会社 The organic-inorganic composite biomaterials and manufacturing method thereof
US6645250B2 (en) 2001-10-30 2003-11-11 Carl W. Schulter Biocompatible form and method of fabrication
US6478825B1 (en) 2001-11-28 2002-11-12 Osteotech, Inc. Implant, method of making same and use of the implant for the treatment of bone defects
US6840961B2 (en) 2001-12-21 2005-01-11 Etex Corporation Machinable preformed calcium phosphate bone substitute material implants
JP4624678B2 (en) 2002-02-21 2011-02-02 パイオニア・サージカル・オーソバイオロジックス,インコーポレイテッド Crosslinking bioactive hydrogel matrix
WO2003089022A1 (en) 2002-04-18 2003-10-30 University Of Florida Biomimetic organic/inorganic composites, processes for their production, and methods of use
US7514249B2 (en) 2002-04-18 2009-04-07 The University Of Florida Research Foundation, Inc. Biomimetic organic/inorganic composites
EP1744793A2 (en) 2003-10-22 2007-01-24 University of Florida Biomimetic organic/inorganic composites, processes for their production, and methods of use
JP3727059B2 (en) 2002-05-01 2005-12-14 独立行政法人物質・材料研究機構 Method for producing a porous composite material
US7166133B2 (en) 2002-06-13 2007-01-23 Kensey Nash Corporation Devices and methods for treating defects in the tissue of a living being
WO2004000270A1 (en) 2002-06-20 2003-12-31 Ltt Bio-Pharma Co., Ltd. Sustained-release composition, process for producing the same and preparation thereof
CN100372579C (en) 2002-11-06 2008-03-05 独立行政法人物质·材料研究机构;宾得株式会社 Cross-linked apatite/collagen porous body containing self-organized apatite/collagen composite and its production method
US7887831B2 (en) 2002-12-26 2011-02-15 Hepacore Ltd. Bone enhancing composite
US6884621B2 (en) 2002-12-23 2005-04-26 Industrial Technology Research Institute Method and carrier for culturing multi-layer tissue in vitro
EP1605862A4 (en) 2003-02-28 2008-09-03 Fibrogen Inc Collagen compositions and biomaterials
EP1462126A1 (en) 2003-03-28 2004-09-29 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Improved Osteoinductive Materials
US8221781B2 (en) 2003-04-11 2012-07-17 Etex Corporation Osteoinductive bone material
WO2004098457A1 (en) 2003-04-30 2004-11-18 Therics, Inc. Bone void filler and method of manufacture
WO2004103422A1 (en) 2003-05-26 2004-12-02 Pentax Corporation Porous composite containing calcium phosphate and process for producing the same
CA2519750A1 (en) 2003-05-28 2004-12-09 Blue Membranes Gmbh Implants with functionalized carbon surfaces
US7252685B2 (en) 2003-06-05 2007-08-07 Sdgi Holdings, Inc. Fusion implant and method of making same
WO2004110308A3 (en) 2003-06-11 2006-10-26 Osteotech Inc Osteoimplants and methods for their manufacture
US6974862B2 (en) 2003-06-20 2005-12-13 Kensey Nash Corporation High density fibrous polymers suitable for implant
US7494950B2 (en) * 2003-09-05 2009-02-24 Synthes (U.S.A.) Bone cement compositions having fiber-reinforcement and/or increased flowability
CN1878565B (en) 2003-09-12 2011-01-12 惠氏公司;埃特克斯公司 Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins
US20050118230A1 (en) 2003-10-22 2005-06-02 Encelle, Inc. Methods and compositions for regenerating connective tissue
GB2407580B (en) 2003-10-28 2009-02-25 Univ Cambridge Tech Biomaterial
EP1701672A4 (en) 2003-12-19 2011-04-27 Osteotech Inc Tissue-derived mesh for orthopedic regeneration
US8328876B2 (en) 2003-12-31 2012-12-11 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
US20070231788A1 (en) 2003-12-31 2007-10-04 Keyvan Behnam Method for In Vitro Assay of Demineralized Bone Matrix
WO2005072656A1 (en) 2004-01-27 2005-08-11 Osteotech, Inc. Stabilized bone graft
US20050272153A1 (en) * 2004-01-27 2005-12-08 Zou Xuenong Bone tissue engineering by ex vivo stem cells ongrowth into three-dimensional trabecular metal
US7534264B2 (en) 2004-01-28 2009-05-19 Ultradent Products, Inc. Delivery system for bone growth promoting material
US7189263B2 (en) 2004-02-03 2007-03-13 Vita Special Purpose Corporation Biocompatible bone graft material
US20050175659A1 (en) 2004-02-09 2005-08-11 Macomber Laurel R. Collagen device and method of preparing the same
US7351280B2 (en) 2004-02-10 2008-04-01 New York University Macroporous, resorbable and injectible calcium phosphate-based cements (MCPC) for bone repair, augmentation, regeneration, and osteoporosis treatment
DE202004005420U1 (en) 2004-03-31 2005-08-18 Technische Universität Dresden Modified calcium phosphate cement
JP2007532211A (en) 2004-04-15 2007-11-15 ニクリス アーゲー Implants and scaffold for tissue engineering having osteogenic matrix composite, a coating of their preparation and osteogenic composite matrix
US8163030B2 (en) 2004-05-06 2012-04-24 Degradable Solutions Ag Biocompatible bone implant compositions and methods for repairing a bone defect
US7252841B2 (en) 2004-05-20 2007-08-07 Skeletal Kinetics, Llc Rapid setting calcium phosphate cements
DE102004030347B4 (en) 2004-06-18 2006-08-03 Aesculap Ag & Co. Kg implant
US9220595B2 (en) 2004-06-23 2015-12-29 Orthovita, Inc. Shapeable bone graft substitute and instruments for delivery thereof
JP4694163B2 (en) * 2004-07-26 2011-06-08 株式会社ジーシー Method for producing a bioabsorbable granular porous bone filling material
US7175858B2 (en) * 2004-07-26 2007-02-13 Skeletal Kinetics Llc Calcium phosphate cements and methods for using the same
WO2006010278A1 (en) 2004-07-26 2006-02-02 Synthes Gmbh Biocompatible, biodegradable polyurethane materials with controlled hydrophobic to hydrophilic ratio
US20090012625A1 (en) * 2004-09-14 2009-01-08 Ying Jackie Y Porous biomaterial-filler composite and method for making the same
US7722895B1 (en) 2004-09-20 2010-05-25 Warsaw Orthopedic, Inc. Osteogenic implants with combined implant materials, and materials and methods for same
US7670384B2 (en) 2004-10-14 2010-03-02 Biomet Manufacturing Corp. Bone graft composition comprising a bone material and a carrier comprising denatured demineralized bone
US7473678B2 (en) * 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US7250550B2 (en) 2004-10-22 2007-07-31 Wright Medical Technology, Inc. Synthetic bone substitute material
JP2008517660A (en) 2004-10-22 2008-05-29 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ Hollow and porous orthopedic or implant for use in dentistry to deliver biological agents
DE102005034420A1 (en) * 2004-12-23 2006-07-06 Ossacur Ag Gel-like material for the filling of bone and / or cartilage defects
KR20070104579A (en) 2004-12-30 2007-10-26 젠자임 코포레이션 Regimens for intra-articular viscosupplementation
WO2006092718A3 (en) 2005-03-04 2007-01-25 Fin Ceramica Faenza Spa Cartilaginiform and osteochondral sustitute comprising a multilayer structure and use thereof
US20060216321A1 (en) 2005-03-24 2006-09-28 Sdgi Holdings, Inc. Solvent based processing technologies for making tissue/polymer composites
US7621963B2 (en) 2005-04-13 2009-11-24 Ebi, Llc Composite bone graft material
JP2006325467A (en) 2005-05-25 2006-12-07 Pentax Corp Collagen-coated carrier and method for producing the collagen-coated carrier
WO2007032390A1 (en) 2005-09-13 2007-03-22 Takiron Co., Ltd. Composite porous material
US7498041B2 (en) 2005-10-12 2009-03-03 Lifenet Health Composition for repair of defects in osseous tissues
US7498040B2 (en) 2005-10-12 2009-03-03 Lifenet Health Compositions for repair of defects in osseous tissues, and methods of making the same
US9005646B2 (en) * 2005-10-12 2015-04-14 Lifenet Health Compositions for repair of defects in tissues, and methods of making the same
US8029575B2 (en) 2005-10-25 2011-10-04 Globus Medical, Inc. Porous and nonporous materials for tissue grafting and repair
CN101365499A (en) 2005-11-01 2009-02-11 骨骼技术股份有限公司 Bone matrix compositions and methods
WO2007056671A1 (en) 2005-11-02 2007-05-18 Osteotech, Inc. Hemostatic bone graft
JP5368102B2 (en) 2005-11-17 2013-12-18 バイオミメティック セラピューティクス, インコーポレイテッド Maxillofacial bone augmentation using rhPDGF-BB and a biocompatible matrix
EP1976460A4 (en) 2006-01-19 2012-06-20 Warsaw Orthopedic Inc Injectable and moldable bone substitute materials
WO2007084609A3 (en) 2006-01-19 2008-01-24 Osteotech Inc Porous osteoimplant
WO2007121345A3 (en) * 2006-04-13 2008-06-26 Univ Case Western Reserve Biomaterial implants
US20070248575A1 (en) 2006-04-19 2007-10-25 Jerome Connor Bone graft composition
US20100209470A1 (en) 2006-05-01 2010-08-19 Warsaw Orthopedic, Inc. An Indiana Corporation Demineralized bone matrix devices
US7771741B2 (en) 2006-05-01 2010-08-10 Warsaw Orthopedic, Inc Demineralized bone matrix devices
US8506983B2 (en) 2006-05-01 2013-08-13 Warsaw Orthopedic, Inc. Bone filler material
US7951200B2 (en) * 2006-07-12 2011-05-31 Warsaw Orthopedic, Inc. Vertebral implant including preformed osteoconductive insert and methods of forming
EP2049591A4 (en) 2006-08-02 2009-08-19 Polynovo Biomaterials Pty Ltd Biocompatible polymer compositions
US20080033572A1 (en) 2006-08-03 2008-02-07 Ebi L.P. Bone graft composites and methods of treating bone defects
US8449622B2 (en) 2006-09-11 2013-05-28 Warsaw Orthopedic, Inc. Multi-phase osteochondral implantable device
EP2073788A2 (en) 2006-09-28 2009-07-01 The Children's Medical Center Corporation Methods and collagen products for tissue repair
DE102006047248B4 (en) * 2006-10-06 2012-05-31 Celgen Ag Three-dimensional artificial callus
US20080147197A1 (en) 2006-12-14 2008-06-19 Mckay William F Biodegradable osteogenic porous biomedical implant with impermeable membrane
US8048857B2 (en) 2006-12-19 2011-11-01 Warsaw Orthopedic, Inc. Flowable carrier compositions and methods of use
US7718616B2 (en) 2006-12-21 2010-05-18 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
US8431148B2 (en) 2007-03-08 2013-04-30 Warsaw Orthopedic, Inc. Bone void filler
US20080233203A1 (en) 2007-03-21 2008-09-25 Jennifer Woodell-May Porous orthapedic materials coated with demineralized bone matrix
EP2139500A4 (en) 2007-03-27 2012-06-20 Univ Southern California Device which enhances the biological activity of locally applied growth factors with particular emphasis on those used for bone repair
WO2008122594A3 (en) 2007-04-05 2009-07-30 Soheil Asgari Partially biodegradable therapeutic implant for bone and cartilage repair
WO2008143867A1 (en) * 2007-05-15 2008-11-27 Stryker Corporation Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
KR101010284B1 (en) 2007-07-04 2011-01-24 재단법인서울대학교산학협력재단 Composition of bone formation with PHSRN-RGD containing oligopeptide
DE102007049931A1 (en) 2007-10-18 2009-04-23 Pharmatech Gmbh Device and method for the continuous production of spherical powder agglomerates
US9056150B2 (en) 2007-12-04 2015-06-16 Warsaw Orthopedic, Inc. Compositions for treating bone defects
US20090148495A1 (en) 2007-12-11 2009-06-11 Hammer Joseph J Optimum Density Fibrous Matrix
US8840913B2 (en) 2008-03-27 2014-09-23 Warsaw Orthopedic, Inc. Malleable multi-component implants and materials therefor
US20100082072A1 (en) 2008-03-28 2010-04-01 Sybert Daryl R Bone anchors for orthopedic applications
US20100004733A1 (en) * 2008-07-02 2010-01-07 Boston Scientific Scimed, Inc. Implants Including Fractal Structures
US9132208B2 (en) * 2008-08-07 2015-09-15 Lifenet Health Composition for a tissue repair implant and methods of making the same
US20100049322A1 (en) * 2008-08-19 2010-02-25 Warsaw Orthopedic, Inc. Osteochondral repair implants and methods
US20100168869A1 (en) 2008-12-31 2010-07-01 Howmedica Osteonics Corp. Tissue integration implant
WO2010117766A1 (en) 2009-03-30 2010-10-14 Osseous Technologies Of America Collagen biomaterial wedge
US20100268227A1 (en) 2009-04-15 2010-10-21 Depuy Products, Inc. Methods and Devices for Bone Attachment
US8397769B2 (en) 2009-04-17 2013-03-19 Abc Pharmatech S.R.L. Apparatus for transferring incoherent or liquid material
WO2010134102A1 (en) 2009-05-19 2010-11-25 Abc Pharmatech S.R.L. Apparatus and method for transferring powdered products
CN102097420B (en) 2009-12-10 2014-08-20 鸿富锦精密工业(深圳)有限公司 Light-emitting diode (LED) and manufacturing method thereof
WO2012068135A1 (en) 2010-11-15 2012-05-24 Zimmer Orthobiologics, Inc. Bone void fillers

Patent Citations (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180605B2 (en) *
US6180606B2 (en) *
US3968567A (en) * 1975-04-21 1976-07-13 Nevins Alan J Endodontic composition and method
US4146936A (en) * 1975-12-30 1979-04-03 Sumitomo Chemical Company Limited Implants for bones, joints and tooth roots
US4192021A (en) * 1976-05-12 1980-03-11 Batelle-Institut e.V. Bone replacement or prosthesis anchoring material
US4202055A (en) * 1976-05-12 1980-05-13 Battelle-Institut E.V. Anchorage for highly stressed endoprostheses
US4429691A (en) * 1979-10-08 1984-02-07 Mitsubishi Mining And Cement Company, Ltd. Method for filling in defects or hollow portions of bones
US4497075A (en) * 1979-10-08 1985-02-05 Mitsubishi Mining & Cement Co., Ltd. Filler for filling in defects or hollow portions of bones
US4761471A (en) * 1980-08-04 1988-08-02 The Regents Of The University Of California Bone morphogenetic protein composition
US4455256A (en) * 1981-05-05 1984-06-19 The Regents Of The University Of California Bone morphogenetic protein
US4394370A (en) * 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4642120A (en) * 1983-03-23 1987-02-10 Ramot University Authority For Applied Research And Industrial Development Ltd. Repair of cartilage and bones
US4795804A (en) * 1983-08-16 1989-01-03 The Regents Of The University Of California Bone morphogenetic agents
US4804744A (en) * 1984-01-04 1989-02-14 International Genetic Engineering, Inc. Osteogenic factors
US4609551A (en) * 1984-03-20 1986-09-02 Arnold Caplan Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites
US4596574A (en) * 1984-05-14 1986-06-24 The Regents Of The University Of California Biodegradable porous ceramic delivery system for bone morphogenetic protein
US4843063A (en) * 1984-07-16 1989-06-27 Collagen Corporation Polypeptide cartilage-inducing factors found in bone
US4774228A (en) * 1984-07-16 1988-09-27 Collagen Corporation Polypeptide cartilage-inducing factors found in bone used in tissue proliferation
US4774322A (en) * 1984-07-16 1988-09-27 Collagen Corporation Polypeptide cartilage-inducing factors found in bone
US4810691A (en) * 1984-07-16 1989-03-07 Collagen Corporation Polypeptide cartilage-inducing factors found in bone
US5001169A (en) * 1984-10-24 1991-03-19 Collagen Corporation Inductive collagen-based bone repair preparations
US4795467A (en) * 1985-03-28 1989-01-03 Collagen Corporation Xenogeneic collagen/mineral preparations in bone repair
US5425770A (en) * 1985-03-28 1995-06-20 Collagen Corporation Calcium phosphate/atelopeptide collagen compositions for bone repair
US4863856A (en) * 1985-04-04 1989-09-05 Verax Corporation Weighted collagen microsponge for immobilizing bioactive materials
US4668295A (en) * 1985-04-25 1987-05-26 University Of Dayton Surgical cements
US5904717A (en) * 1986-01-28 1999-05-18 Thm Biomedical, Inc. Method and device for reconstruction of articular cartilage
US4774227A (en) * 1986-02-14 1988-09-27 Collagen Corporation Collagen compositions for bone repair containing autogeneic marrow
US5904718A (en) * 1986-03-27 1999-05-18 Biocoll Laboratories, Inc. Delayed drug delivery system
US5106748A (en) * 1986-07-01 1992-04-21 Genetics Institute, Inc. Dna sequences encoding 5 proteins
US5123923A (en) * 1986-07-16 1992-06-23 La Cellulose Du Pin & Universite De Bordeaux Ii Biocompatible, hydrophilic material method of manufacture and uses of same
US5035715A (en) * 1986-11-06 1991-07-30 Collagen Corporation Gamma irradiation of collagen/mineral mixtures
US5085861A (en) * 1987-03-12 1992-02-04 The Beth Israel Hospital Association Bioerodable implant composition comprising crosslinked biodegradable polyesters
US4843112A (en) * 1987-03-12 1989-06-27 The Beth Israel Hospital Association Bioerodable implant composition
US4863732A (en) * 1987-12-16 1989-09-05 Collagen Corporation Injectable composition for inductive bone repair
US5137534A (en) * 1988-01-11 1992-08-11 Asahi Kogaku Kogyo K.K. Method for producing dental and medical bone prosthesis and bone prosthesis produced thereby
US5236704A (en) * 1988-01-28 1993-08-17 Sumitomo Pharmaceuticals Co., Ltd. Controlled release formulation
US4919670A (en) * 1988-02-03 1990-04-24 Intermedics Orthopedics, Inc. Modular humeral prosthesis
US5028695A (en) * 1988-03-11 1991-07-02 Chemokol Gesellschaft Zur Entwicklung Von Kollagenprodukten Process for the manufacture of collagen membranes used for hemostasis, the dressing of wounds and for implants
US5496552A (en) * 1988-04-08 1996-03-05 Stryker Corporation Osteogenic devices
US5814604A (en) * 1988-04-08 1998-09-29 Stryker Corporation Methods for inducing endochondral bone formation comprising administering CBMP-2A, CBMP-2B, and/or virants thereof
US5108753A (en) * 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
US5047031A (en) * 1988-04-20 1991-09-10 Norian Corporation In situ calcium phosphate minerals method
US5417975A (en) * 1988-06-02 1995-05-23 Osteomedical Limited Chemical Compound
US5024841A (en) * 1988-06-30 1991-06-18 Collagen Corporation Collagen wound healing matrices and process for their production
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
US5552454A (en) * 1988-08-09 1996-09-03 Henkel Kommanditgesellschaft Auf Aktien New materials for bone replacement and for joining bones or prostheses
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5108436A (en) * 1988-09-29 1992-04-28 Collagen Corporation Implant fixation
US5599552A (en) * 1989-07-24 1997-02-04 Atrix Laboratories, Inc. Biodegradable polymer composition
US4997446A (en) * 1989-09-14 1991-03-05 Intermedics Orthopedics, Inc. Method and apparatus for osseous contour reconstruction
US5932207A (en) * 1989-11-03 1999-08-03 Schmidt; Karlheinz Complex active ingredient for the production of biological parts, especially organs for living organisms: method for the production of the same and its use
US5236456A (en) * 1989-11-09 1993-08-17 Osteotech, Inc. Osteogenic composition and implant containing same
US5405390A (en) * 1989-11-09 1995-04-11 Osteotech, Inc. Osteogenic composition and implant containing same
US5231169A (en) * 1990-10-17 1993-07-27 Norian Corporation Mineralized collagen
US5811094A (en) * 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
US5393739A (en) * 1990-11-30 1995-02-28 Celtrix Pharmaceuticals, Inc. Use of bone morphogenetic protein in synergistic combination with TGF-β for bone repair
US5208219A (en) * 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
US5290763A (en) * 1991-04-22 1994-03-01 Intermedics Orthopedics/Denver, Inc. Osteoinductive protein mixtures and purification processes
US5443531A (en) * 1991-04-29 1995-08-22 South African Medical Research Council Delivery system for biologically active growth or morphogenetic factors and to a method for preparing such a delivery system
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5306303A (en) * 1991-11-19 1994-04-26 The Medical College Of Wisconsin, Inc. Bone induction method
US5769897A (en) * 1991-12-13 1998-06-23 Haerle; Anton Synthetic bone
US5204382A (en) * 1992-02-28 1993-04-20 Collagen Corporation Injectable ceramic compositions and methods for their preparation and use
US5433751A (en) * 1992-04-03 1995-07-18 Inoteb Bone prosthesis material containing calcium carbonate particles dispersed in a bioresorbable polymer matrix
US5532217A (en) * 1992-04-24 1996-07-02 Silver; Frederick H. Process for the mineralization of collagen fibers, product produced thereby and use thereof to repair bone
US5916553A (en) * 1992-09-17 1999-06-29 Schmidt; Karlheinz Complex for inducing bone growth in the mastoid cavity
US5531791A (en) * 1993-07-23 1996-07-02 Bioscience Consultants Composition for repair of defects in osseous tissues, method of making, and prosthesis
US5426769A (en) * 1993-08-26 1995-06-20 Metalink Corp. System and method for producing input/output expansion for single chip microcomputers
US5935594A (en) * 1993-10-28 1999-08-10 Thm Biomedical, Inc. Process and device for treating and healing a tissue deficiency
US6264701B1 (en) * 1994-05-13 2001-07-24 Kensey Nash Corporation Device and methods for in vivo culturing of diverse tissue cells
US6183515B1 (en) * 1994-08-08 2001-02-06 Board Of Regents, The University Of Texas System Artificial bone implants
US5639402A (en) * 1994-08-08 1997-06-17 Barlow; Joel W. Method for fabricating artificial bone implant green parts
US6180605B1 (en) * 1994-09-28 2001-01-30 Gensci Orthobiologics, Inc. Composition with enhanced osteogenic potential, method for making the same and therapeutic uses thereof
US5707962A (en) * 1994-09-28 1998-01-13 Gensci Regeneration Sciences Inc. Compositions with enhanced osteogenic potential, method for making the same and therapeutic uses thereof
US6180606B1 (en) * 1994-09-28 2001-01-30 Gensci Orthobiologics, Inc. Compositions with enhanced osteogenic potential, methods for making the same and uses thereof
US5547378A (en) * 1994-10-21 1996-08-20 Linkow; Leonard I. Apparatus and method for closing a sinus opening during a dental implant operation
US6214368B1 (en) * 1995-05-19 2001-04-10 Etex Corporation Bone substitution material and a method of its manufacture
US6277151B1 (en) * 1995-05-19 2001-08-21 Etex Corporation Cartilage growth from cell seeded ceramic compositions
US5910492A (en) * 1995-06-05 1999-06-08 Takeda Chemical Industries, Ltd. Osteogenic promoting pharmaceutical composition
US5776193A (en) * 1995-10-16 1998-07-07 Orquest, Inc. Bone grafting matrix
US6261565B1 (en) * 1996-03-13 2001-07-17 Archer Daniels Midland Company Method of preparing and using isoflavones
US6018095A (en) * 1996-06-14 2000-01-25 Bioland Method for preparing an implantable composite material, resulting material, implant including said material, and kit therefor
US6346123B1 (en) * 1996-10-24 2002-02-12 Sdgi Holdings, Inc. Ceramic fusion implants and compositions
US6679918B1 (en) * 1997-02-13 2004-01-20 Centerpulse Biologics Inc. Implantable putty material
US6071982A (en) * 1997-04-18 2000-06-06 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
US6335007B1 (en) * 1997-05-28 2002-01-01 Yasuhiko Shimizu Collagen gel
US6033438A (en) * 1997-06-03 2000-03-07 Sdgi Holdings, Inc. Open intervertebral spacer
US6582471B1 (en) * 1997-08-14 2003-06-24 Sulzer Innotec Ag Composition and device for in vivo cartilage repair
US6514514B1 (en) * 1997-08-14 2003-02-04 Sùlzer Biologics Inc. Device and method for regeneration and repair of cartilage lesions
US6187329B1 (en) * 1997-12-23 2001-02-13 Board Of Regents Of The University Of Texas System Variable permeability bone implants, methods for their preparation and use
US20020076429A1 (en) * 1998-01-28 2002-06-20 John F. Wironen Bone paste subjected to irradiative and thermal treatment
US6911212B2 (en) * 1998-02-27 2005-06-28 Musculoskeletal Transplant Foundation Malleable putty and flowable paste with allograft bone having residual calcium for filling bone defects
US6384197B1 (en) * 1998-03-24 2002-05-07 Merck Patent Gesellschaft Process for the preparation of mineralized collagen fibrils and their use as bone substitute material
US6384196B1 (en) * 1998-03-24 2002-05-07 Merck Patent Gesellschaft Process for the preparation of mineralized collagen fibrils and their uses as bone substitute material
US6214049B1 (en) * 1999-01-14 2001-04-10 Comfort Biomedical, Inc. Method and apparatus for augmentating osteointegration of prosthetic implant devices
US20040002558A1 (en) * 1999-02-04 2004-01-01 Mckay William F. Osteogenic paste compositions and uses thereof
US6376211B1 (en) * 1999-07-12 2002-04-23 Xoma Technology Ltd. Agents and methods for inhibiting F1/F0 ATPase
US6280191B1 (en) * 1999-09-03 2001-08-28 Christopher B. Gordon Distractor suitable for permanent implantation into bone
US20020082220A1 (en) * 2000-06-29 2002-06-27 Hoemann Caroline D. Composition and method for the repair and regeneration of cartilage and other tissues
US20020114795A1 (en) * 2000-12-22 2002-08-22 Thorne Kevin J. Composition and process for bone growth and repair
US20040062816A1 (en) * 2002-07-31 2004-04-01 Atkinson Brent L. Bone repair putty

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497236B2 (en) 1998-02-13 2013-07-30 Zimmer Orthobiologics, Inc. Implantable putty material
US20040081704A1 (en) * 1998-02-13 2004-04-29 Centerpulse Biologics Inc. Implantable putty material
US8690874B2 (en) 2000-12-22 2014-04-08 Zimmer Orthobiologics, Inc. Composition and process for bone growth and repair
US8419802B2 (en) 2002-06-13 2013-04-16 Kensey Nash Bvf Technology, Llc Devices and methods for treating defects in the tissue of a living being
US8623094B2 (en) 2002-06-13 2014-01-07 Kensey Nash Bvf Technology Llc Devices and methods for treating defects in the tissue of a living being
US8435306B2 (en) 2002-06-13 2013-05-07 Kensey Nash Bvf Technology Llc Devices and methods for treating defects in the tissue of a living being
US8425619B2 (en) 2002-06-13 2013-04-23 Kensey Nash Bvf Technology, Llc Devices and methods for treating defects in the tissue of a living being
US8163032B2 (en) 2002-06-13 2012-04-24 Kensey Nash Bvf Technology, Llc Devices and methods for treating defects in the tissue of a living being
US9283074B2 (en) 2002-06-13 2016-03-15 Kensey Nash Bvf Technology, Llc Devices and methods for treating defects in the tissue of a living being
US8742072B2 (en) 2006-12-21 2014-06-03 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
US7718616B2 (en) 2006-12-21 2010-05-18 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
US20080152687A1 (en) * 2006-12-21 2008-06-26 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
US20080221511A1 (en) * 2007-03-08 2008-09-11 Warsaw Orthopedic, Inc. Bone void filler
US8431148B2 (en) 2007-03-08 2013-04-30 Warsaw Orthopedic, Inc. Bone void filler
US20090112317A1 (en) * 2007-10-25 2009-04-30 Collagen Matrix, Inc. Calcium-Containing Bone Implants
US7998499B2 (en) * 2007-10-25 2011-08-16 Collagen Matrix, Inc. Calcium-containing bone implants
US20090246244A1 (en) * 2008-03-27 2009-10-01 Warsaw Orthopedic, Inc. Malleable multi-component implants and materials therefor
US8840913B2 (en) * 2008-03-27 2014-09-23 Warsaw Orthopedic, Inc. Malleable multi-component implants and materials therefor
US8613938B2 (en) 2010-11-15 2013-12-24 Zimmer Orthobiologics, Inc. Bone void fillers
WO2012068135A1 (en) 2010-11-15 2012-05-24 Zimmer Orthobiologics, Inc. Bone void fillers
US8551525B2 (en) 2010-12-23 2013-10-08 Biostructures, Llc Bone graft materials and methods
US9220596B2 (en) 2010-12-23 2015-12-29 Biostructures, Llc Bone graft materials and methods
US20150110890A1 (en) * 2013-10-18 2015-04-23 Fortus Medical, Inc. Bone marrow aspirate enhanced bone graft

Also Published As

Publication number Publication date Type
WO2002051449A3 (en) 2002-09-06 application
US20020114795A1 (en) 2002-08-22 application
CA2446840A1 (en) 2002-07-04 application
EP1365792A2 (en) 2003-12-03 application
JP2004520106A (en) 2004-07-08 application
WO2002051449A2 (en) 2002-07-04 application
US20110165199A1 (en) 2011-07-07 application
US8690874B2 (en) 2014-04-08 grant

Similar Documents

Publication Publication Date Title
Yang et al. Osteogenesis in extraskeletally implanted porous calcium phosphate ceramics: variability among different kinds of animals
Winn et al. Sustained release emphasizing recombinant human bone morphogenetic protein-2
Driessens et al. Osteotransductive bone cements
Schmitz et al. Reconstruction of bone using calcium phosphate bone cements: a critical review
Cornell Osteoconductive materials and their role as substitutes for autogenous bone grafts
Schwartz et al. Ability of deproteinized cancellous bovine bone to induce new bone formation
Browaeys et al. A literature review on biomaterials in sinus augmentation procedures
Takahashi et al. Enhanced osteoinduction by controlled release of bone morphogenetic protein-2 from biodegradable sponge composed of gelatin and β-tricalcium phosphate
PINHOLT et al. Alveolar ridge augmentation in rats by Bio‐Oss
Mata et al. Bone regeneration mediated by biomimetic mineralization of a nanofiber matrix
Burg et al. Biomaterial developments for bone tissue engineering
Geiger et al. Collagen sponges for bone regeneration with rhBMP-2
Chung et al. Enhanced bone regeneration with BMP-2 loaded functional nanoparticle–hydrogel complex
Cancedda et al. A tissue engineering approach to bone repair in large animal models and in clinical practice
US6953594B2 (en) Method of preparing a poorly crystalline calcium phosphate and methods of its use
US5585116A (en) Method of manufacture of a material for osteoplasty from a natural bone tissue and material obtained thereby
US5604204A (en) Method of inducing bone growth using TGF-β
Kirker-Head Potential applications and delivery strategies for bone morphogenetic proteins
Wise Encyclopedic Handbook of Biomaterials and Bioengineering: v. 1-2. Applications
Apelt et al. In vivo behavior of three different injectable hydraulic calcium phosphate cements
LeGeros Calcium phosphate-based osteoinductive materials
Okubo et al. Osteoinduction by recombinant human bone morphogenetic protein‐2 at intramuscular, intermuscular, subcutaneous and intrafatty sites
Klinge et al. Osseous response to implanted natural bone mineral and synthetic hydroxylapatite ceramic in the repair of experimental skull bone defects
Lo et al. Studies of bone morphogenetic protein-based surgical repair
Asahina et al. Repair of bone defect in primate mandible using a bone morphogenetic protein (BMP)-hydroxyapatite-collagen composite

Legal Events

Date Code Title Description
AS Assignment

Owner name: ZIMMER ORTHOBIOLOGICS, INC., TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THORNE, KEVIN J.;REEL/FRAME:018029/0418

Effective date: 20060621